Anti-il-13 antibodies and uses thereof

Abstract

Aspects of the application provide anti-IL-13 antibodies and methods of using the same in treating IL-13-mediated diseases (e.g., allergic disease or other inflammatory diseases).

Description

ANTI-IL-13 ANTIBODIES AND USES THEREOFRELATED APPLICATIONS

[0001] This application claims benefit under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 63 / 744,108, filed January 10, 2025, entitled “Anti-IL-13 Antibodies and Uses Thereof’, the entire contents of which are incorporated herein by reference.REFERENCE TO AN ELECTRONIC SEQUENCE LISTING

[0002] The contents of the electronic sequence listing (A140770009WO00-SEQ-LJG.xml; Size: 109,293 bytes; and Date of Creation: December 29, 2025) are herein incorporated by reference in their entirety.BACKGROUND

[0003] Interleukin- 13 (IL-13) is a cytokine primarily produced by immune cells, such as type- 2 CD4 T helper cells (Th2 cells), mast cell, and eosinophils. IL- 13 is involved in the immune response, especially allergic diseases, fibrosis, parasitic infections, and inflammatory disorders.SUMMARY

[0004] The present disclosure, at least in part, is based on the development of humanized anti-IL-13 antibodies and their variants thereof, which have equivalent or higher binding affinity and specificity to IL-13 relative to, e.g., an existing humanized anti-IL-13 antibody humanized from the same murine parental anti-IL-13 antibody. In some embodiments, a humanized anti-IL-13 antibody described herein has improved developability (e.g., higher yield during manufacturing relative to, for example, an existing humanized anti-IL-13 antibody humanized from the same murine parental anti-IL-13 antibody). Also provided are use of the anti-IL-13 antibodies and their variants in research, diagnostic / detection, and therapeutic applications.

[0005] Aspects of the disclosure provide an anti-interleukin- 13 (IL- 13) antibody that is, inter alia, obtainable at high expression titer.

[0006] In some aspects, provided herein is an anti-IL-13 antibody comprising a heavy chain complementarity determining region 1 (HC CDR1), HC CDR2, and HC CDR3 of any one of the variable heavy chain (VH) domains in Table 2; and / or a light chain CDR1 (LC CDR1), LC CDR2, and LC CDR3 of any one of the variable light chain domains (VL) in Table 2, wherein the anti-IL-13 antibody is obtainable at high expression titer.

[0007] In some aspects, provided herein is a humanized anti-IL-13 antibody that is obtained at high expression titer.

[0008] In some embodiments, provided herein is an anti-IL-13 antibody comprising a HC CDR1, a HC CDR2, and a HC CDR3 of a VH domain comprising the amino acid sequence of #14704898vlSEQ ID NO: 19, and a LC CDR1, LC CDR2, and LC CDR3 of a VL comprising the amino acid sequence of SEQ ID NO: 63.

[0009] In some embodiments, provided herein is an anti-IL-13 antibody comprising a HC CDR1, HC CDR2, and HC CDR3 of a VH having the amino acid sequence of SEQ ID NO: 24, and a LC CDR1, LC CDR2, and LC CDR3 of a VL having the amino acid sequence of SEQ ID NO: 66.

[0010] In some embodiments, provided herein is an anti-IL-13 antibody comprising a HC CDR1, HC CDR2, and HC CDR3 of a VH having the amino acid sequence of SEQ ID NO: 24, and a LC CDR1, LC CDR2, and LC CDR3 of a VL having the amino acid sequence of SEQ ID NO: 80.

[0011] In some embodiments, provided herein is an anti-IL-13 antibody comprising a HC CDR1, HC CDR2, and HC CDR3 of a VH having the amino acid sequence of SEQ ID NO: 27, and a LC CDR1, LC CDR2, and LC CDR3 of a VL having the amino acid sequence of SEQ ID NO: 71.

[0012] In some embodiments, provided herein is an anti-IL-13 antibody comprising a HC CDR1, HC CDR2, and HC CDR3 of a VH having the amino acid sequence of SEQ ID NO: 32, and a LC CDR1, LC CDR2, and LC CDR3 of a VL having the amino acid sequence of SEQ ID NO: 68.

[0013] In some embodiments, provided herein is an anti-IL-13 antibody comprising a HC CDR1, HC CDR2, and HC CDR3 of a VH having the amino acid sequence of SEQ ID NO: 34, and a LC CDR1, LC CDR2, and LC CDR3 of a VL having the amino acid sequence of SEQ ID NO: 76.

[0014] In some embodiments, provided herein is an anti-IL-13 antibody comprising a HC CDR1, HC CDR2, and HC CDR3 of a VH having the amino acid sequence of SEQ ID NO: 34, and a LC CDR1, LC CDR2, and LC CDR3 of a VL having the amino acid sequence of SEQ ID NO: 80.

[0015] In some embodiments, provided herein is an anti-IL-13 antibody comprising a HC CDR1, HC CDR2, and HC CDR3 of a VH having the amino acid sequence of SEQ ID NO: 36, and a LC CDR1, LC CDR2, and LC CDR3 of a VL having the amino acid sequence of SEQ ID NO: 71.

[0016] In some embodiments, provided herein is an anti-IL-13 antibody comprising a HC CDR1, HC CDR2, and HC CDR3 of a VH having the amino acid sequence of SEQ ID NO: 39, and a LC CDR1, LC CDR2, and LC CDR3 of a VL having the amino acid sequence of SEQ ID NO: 74.

[0017] In some embodiments, the anti-IL-13 antibody comprises an HC CDR1 having the #14704898vlamino acid sequence of SEQ ID NO: 2, a HC CDR2 having the amino acid sequence of SEQ ID NO: 20, a HC CDR3 having the amino acid sequence of SEQ ID NO: 4, a LC CDR1 having the amino acid sequence of SEQ ID NO: 44, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46.

[0018] In some embodiments, the anti-IL-13 antibody comprises an HC CDR1 having the amino acid sequence of SEQ ID NO: 2, a HC CDR2 having the amino acid sequence of SEQ ID NO: 3, a HC CDR3 having the amino acid sequence of SEQ ID NO: 4, a LC CDR1 having the amino acid sequence of SEQ ID NO: 69, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46.

[0019] In some embodiments, the anti-IL-13 antibody comprises an HC CDR1 having the amino acid sequence of SEQ ID NO: 2, a HC CDR2 having the amino acid sequence of SEQ ID NO: 28, a HC CDR3 having the amino acid sequence of SEQ ID NO: 4, a LC CDR1 having the amino acid sequence of SEQ ID NO: 33, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46.

[0020] In some embodiments, the anti-IL-13 antibody comprises an HC CDR1 having the amino acid sequence of SEQ ID NO: 2, a HC CDR2 having the amino acid sequence of SEQ ID NO: 28, a HC CDR3 having the amino acid sequence of SEQ ID NO: 4, a LC CDR1 having the amino acid sequence of SEQ ID NO: 69, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46.

[0021] In some embodiments, the anti-IL-13 antibody comprises an HC CDR1 having the amino acid sequence of SEQ ID NO: 2, a HC CDR2 having the amino acid sequence of SEQ ID NO: 20, a HC CDR3 having the amino acid sequence of SEQ ID NO: 4, a LC CDR1 having the amino acid sequence of SEQ ID NO: 69, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46.

[0022] In some embodiments, the anti-IL-13 antibody comprises an HC CDR1 having the amino acid sequence of SEQ ID NO: 2, a HC CDR2 having the amino acid sequence of SEQ ID NO: 37, a HC CDR3 having the amino acid sequence of SEQ ID NO: 4, a LC CDR1 having the amino acid sequence of SEQ ID NO: 44, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46.

[0023] In some embodiments, the anti-IL-13 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 19, and a VL having the amino acid sequence of SEQ ID NO: 63.

[0024] In some embodiments, the anti-IL-13 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 24, and a VL having the amino acid sequence of SEQ ID NO: 66.

[0025] In some embodiments, the anti-IL-13 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 24, and a VL having the amino acid sequence of SEQ ID NO: 80. #14704898vl

[0026] In some embodiments, the anti-IL-13 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 27, and a VL having the amino acid sequence of SEQ ID NO: 71.

[0027] In some embodiments, the anti-IL-13 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 32, and a VL having the amino acid sequence of SEQ ID NO: 68.

[0028] In some embodiments, the anti-IL-13 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 34, and a VL having the amino acid sequence of SEQ ID NO: 76.

[0029] In some embodiments, the anti-IL-13 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 34, and a VL having the amino acid sequence of SEQ ID NO: 80.

[0030] In some embodiments, the anti-IL-13 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 36, and a VL having the amino acid sequence of SEQ ID NO: 71.

[0031] In some embodiments, the anti-IL-13 antibody comprises a VH having the amino acid sequence of SEQ ID NO: 39, and a VL having the amino acid sequence of SEQ ID NO: 74.

[0032] In some embodiments, the anti-IL-13 antibody comprises: a VH domain encoded by a sequence selected from Table 4a; and a VL domain encoded by a sequence selected from Table 4b. In some embodiments, the anti-IL-13 antibody further comprises a heavy chain constant domain. In some embodiments, the anti-IL-13 antibody further comprises a light chain constant domain.

[0033] In some aspects, provided herein is an isolated nucleic acid encoding the VH and / or the VL of an anti-IL-13 antibody provided herein.

[0034] In some embodiments, the isolated nucleic acid comprises a nucleic acid sequence of SEQ ID NO: 182, and / or a nucleic acid sequence of SEQ ID NO: 225.

[0035] In some embodiments, the isolated nucleic acid comprises a nucleic acid sequence of SEQ ID NO: 183, and / or a nucleic acid sequence of SEQ ID NO: 226.

[0036] In some embodiments, the isolated nucleic acid comprises a nucleic acid sequence of SEQ ID NO: 183, and / or a nucleic acid sequence of SEQ ID NO: 231.

[0037] In some embodiments, the isolated nucleic acid comprises a nucleic acid sequence of SEQ ID NO: 184, and / or a nucleic acid sequence of SEQ ID NO: 228.

[0038] In some embodiments, the isolated nucleic acid comprises a nucleic acid sequence of SEQ ID NO: 185, and / or a nucleic acid sequence of SEQ ID NO: 227.

[0039] In some embodiments, the isolated nucleic acid comprises a nucleic acid sequence of SEQ ID NO: 186, and / or a nucleic acid sequence of SEQ ID NO: 230.

[0040] In some embodiments, the isolated nucleic acid comprises a nucleic acid sequence of SEQ ID NO: 186, and / or a nucleic acid sequence of SEQ ID NO: 231.

[0041] In some embodiments, the isolated nucleic acid comprises a nucleic acid sequence of SEQ ID NO: 187, and / or a nucleic acid sequence of SEQ ID NO: 228.#14704898vl

[0042] In some embodiments, the isolated nucleic acid comprises a nucleic acid sequence of SEQ ID NO: 188, and / or a nucleic acid sequence of SEQ ID NO: 229.

[0043] In some aspects, provided herein is an expression vector comprising an isolated nucleic acid provided herein.

[0044] In some aspects, provided herein is a host cell comprising an anti-IL-13 antibody, isolated nucleic acid, or expression vector provided herein. In some embodiments, the host cell is a Chinese hamster ovary (CHO) cell or a human embryonic kidney 293 (HEK293) cell.

[0045] In some aspects, provided herein is a method of producing an anti-IL-13 antibody provided herein, the method comprising: (i) culturing the host cell of claim 11 or 12 under conditions for expressing the anti-IL-13 antibody; and (ii) harvesting the anti-IL-13 antibody from a host cell lysate or culture supernatant.

[0046] In some embodiments, the method further comprises purifying the anti-IL-13 antibody.

[0047] In some aspects, provided herein is a composition comprising an anti-IL-13 antibody, isolated nucleic acid, expression vector, or host cell provided herein. In some aspects, the composition comprises a pharmaceutically acceptable carrier.

[0048] In some aspects, provided herein is a method comprising administering to a subject in need thereof an effective amount of an anti-IL-13 antibody, isolated nucleic acid, expression vector, host cell, or composition provided herein. In some embodiments, the subject has a skin barrier defect.

[0049] In some aspects, provided herein is a method of treating a skin barrier defect, the method comprising administering to a subject in need thereof an effective amount of an anti-IL-13 antibody, isolated nucleic acid, expression vector, host cell, or composition provided herein.

[0050] In some embodiments, the skin barrier defect is associated with Netherton syndrome, atopic dermatitis, eosinophilic esophagitis, prurigo nodularis, chronic pruritus of unknown origin (CPUO), dry skin, asthma, ichthyosis vulgaris, or itch or chronic itch.

[0051] In some embodiments, the subject has atopic dermatitis.

[0052] In some aspects, provided herein is an antibody comprising a heavy chain variable region that comprises a HC CDR1, HC CDR2, and HC CDR3 and a HC FW1, a HC FW2, a HC FW3 and a HC FW4 comprising the amino acid sequence of the HC FW1, HC FW2, HC FW3, and HC FW4 in Table 2, and a LC CDR1, LC CDR2, and LC CDR3 and a LC FW1, a LC FW2, a LC FW3 and a LC FW4 comprising the amino acid sequence of any one of the HC FW1, HC FW2, HC FW3, and HC FW4 set forth in Table 2.

[0053] In some aspects, provided herein is an antibody comprising: (a) a variable heavy chain (VH) domain in format heavy chain (HC) framework 1 (HC FW1)-HC complementarity determining 1 (CDRl)-HC FW2-HC CDR2-HC FW3-HC CDR3-HC FW4, wherein the HC #14704898vlFW1, HC FW2, HC FW3, and HC FW4 comprise the amino acid sequence of any one of the HC FW1, HC FW2, HC FW3, and HC FW4 selected from Table 3a; and (b) a variable light chain domain (VL) in format light chain (LC) FW1-LC CDR1-LC FW2-LC CDR2-LC FW3-LC CDR3-LC FW4, wherein the LC FW1, LC FW2, LC FW3, and LC FW4 comprise the amino acid sequence of any one of the LC FW1, LC FW2, LC FW3, and LC FW4 selected from Table 3b.

[0054] In some embodiments, the antibody comprises: (a) an HC FW1, HC FW2, HC FW3, and HC FW4 of a VH having the amino acid sequence of SEQ ID NO: 19; (b) an HC FW1, HC FW2, HC FW3, and HC FW4 of a VH having the amino acid sequence of SEQ ID NO: 24; (c) an HC FW1, HC FW2, HC FW3, and HC FW4 of a VH having the amino acid sequence of SEQ ID NO: 27; (d) an HC FW1, HC FW2, HC FW3, and HC FW4 of a VH having the amino acid sequence of SEQ ID NO: 32; (e) an HC FW1, HC FW2, HC FW3, and HC FW4 of a VH having the amino acid sequence of SEQ ID NO: 34; (f) an HC FW1, HC FW2, HC FW3, and HC FW4 of a VH having the amino acid sequence of SEQ ID NO: 36; or (g) an HC FW1, HC FW2, HC FW3, and HC FW4 of a VH having the amino acid sequence of SEQ ID NO: 39.

[0055] In some embodiments, the antibody comprises: (a) a HC FW1 having the amino acid sequence of SEQ ID NO: 21, a HC FW2 having the amino acid sequence of SEQ ID NO: 22, a HC FW3 having the amino acid sequence of SEQ ID NO: 23, and a HC FW4 having the amino acid sequence of SEQ ID NO: 8; (b) a HC FW1 having the amino acid sequence of SEQ ID NO: 25, a HC FW2 having the amino acid sequence of SEQ ID NO: 6, a HC FW3 having the amino acid sequence of SEQ ID NO: 26, and a HC FW4 having the amino acid sequence of SEQ ID NO: 8; (c) a HC FW1 having the amino acid sequence of SEQ ID NO: 29, a HC FW2 having the amino acid sequence of SEQ ID NO: 30, a HC FW3 having the amino acid sequence of SEQ ID NO: 31, and a HC FW4 having the amino acid sequence of SEQ ID NO: 8; (d) a HC FW 1 having the amino acid sequence of SEQ ID NO: 29, a HC FW2 having the amino acid sequence of SEQ ID NO: 30, a HC FW3 having the amino acid sequence of SEQ ID NO: 33, and a HC FW4 having the amino acid sequence of SEQ ID NO: 8; (e) a HC FW1 having the amino acid sequence of SEQ ID NO: 35, a HC FW2 having the amino acid sequence of SEQ ID NO: 22, a HC FW3 having the amino acid sequence of SEQ ID NO: 23, and a HC FW4 having the amino acid sequence of SEQ ID NO: 8; (f) a HC FW1 having the amino acid sequence of SEQ ID NO: 21, a HC FW2 having the amino acid sequence of SEQ ID NO: 22, a HC FW3 having the amino acid sequence of SEQ ID NO: 38, and a HC FW4 having the amino acid sequence of SEQ ID NO: 8; or (g) a HC FW1 having the amino acid sequence of SEQ ID NO: 40, a HC FW2 having the amino acid sequence of SEQ ID NO: 41, a HC FW3 having the amino acid sequence of SEQ ID NO: 42, and a HC FW4 having the amino acid sequence of SEQ ID NO: 8.#14704898vl

[0056] In some embodiments, the antibody comprises: (a) a LC FW1, LC FW2, LC FW3, and LC FW4 of a VL having the amino acid sequence of SEQ ID NO: 63; (b) a LC FW1, LC FW2, LC FW3, and LC FW4 of a VL having the amino acid sequence of SEQ ID NO: 66; (c) a LC FW1, LC FW2, LC FW3, and LC FW4 of a VL having the amino acid sequence of SEQ ID NO: 80; (d) a LC FW1, LC FW2, LC FW3, and LC FW4 of a VL having the amino acid sequence of SEQ ID NO: 71; (e) a LC FW1, LC FW2, LC FW3, and LC FW4 of a VL having the amino acid sequence of SEQ ID NO: 68; (f) a LC FW1, LC FW2, LC FW3, and LC FW4 of a VL having the amino acid sequence of SEQ ID NO: 76; or g) a LC FW1, LC FW2, LC FW3, and LC FW4 of a VL having the amino acid sequence of SEQ ID NO: 74.

[0057] In some embodiments, the antibody comprises: a) a LC FW1 having the amino acid sequence of SEQ ID NO: 47, a LC FW2 having the amino acid sequence of SEQ ID NO: 48, a LC FW3 having the amino acid sequence of SEQ ID NO: 64, a LC FW4 having the amino acid sequence of SEQ ID NO: 65; (b) a LC FW1 having the amino acid sequence of SEQ ID NO: 67, a LC FW2 having the amino acid sequence of SEQ ID NO: 48, a LC FW3 having the amino acid sequence of SEQ ID NO: 64, a LC FW4 having the amino acid sequence of SEQ ID NO: 65; c) a LC FW1 having the amino acid sequence of SEQ ID NO: 77, a LC FW2 having the amino acid sequence of SEQ ID NO: 78, a LC FW3 having the amino acid sequence of SEQ ID NO: 81, a LC FW4 having the amino acid sequence of SEQ ID NO: 65; d) a LC FW1 having the amino acid sequence of SEQ ID NO: 72, a LC FW2 having the amino acid sequence of SEQ ID NO: 48, a LC FW3 having the amino acid sequence of SEQ ID NO: 73, a LC FW4 having the amino acid sequence of SEQ ID NO: 65; e) a LC FW1 having the amino acid sequence of SEQ ID NO: 70, a LC FW2 having the amino acid sequence of SEQ ID NO: 57, a LC FW3 having the amino acid sequence of SEQ ID NO: 58, a LC FW4 having the amino acid sequence of SEQ ID NO: 65; (f) a LC FW1 having the amino acid sequence of SEQ ID NO: 77, a LC FW2 having the amino acid sequence of SEQ ID NO: 78, a LC FW3 having the amino acid sequence of SEQ ID NO: 79, a LC FW4 having the amino acid sequence of SEQ ID NO: 65; or (g) a LC FW1 having the amino acid sequence of SEQ ID NO: 72, a LC FW2 having the amino acid sequence of SEQ ID NO: 48, a LC FW3 having the amino acid sequence of SEQ ID NO: 75, a LC FW4 having the amino acid sequence of SEQ ID NO: 65.

[0058] In some aspects, provided herein is an antibody comprising an antigen-specific binding site and a framework, wherein the antigen- specific binding site comprises a heavy chain complementarity determining region 1 (HC CDR1), HC CDR2, and HC CDR3; and wherein the HC CDR1, HC CDR2, and HC CDR3 are grafted into a heavy chain framework (HC FW) of any one of the HC variable domains (VL) in Table 2.

[0059] In some aspects, provided herein is an antibody comprising an antigen-specific binding #14704898vlsite and a framework, wherein the antigen-specific binding site comprises a light chain complementarity determining region 1 (LC CDR1), LC CDR2, and LC CDR3; and wherein the LC CDR1, LC CDR2, and LC CDR3 are grafted into a light chain framework (LC FW) of any one of the LC variable domains (VL) in Table 2.

[0060] In some aspects, provided herein is a method of producing a humanized antibody, the method comprising engineering a recombinant nucleic acid to express an antibody having a selected set of complementarity determining regions (CDRs) engrafted in any one of the framework (FW) sets selected from Table 3a and / or Table 3b.

[0061] The foregoing and other aspects, implementations, acts, functionalities, features, and embodiments of the present teachings can be more fully understood from the following description.DETAILED DESCRIPTION

[0062] The present disclosure, at least in part, is based on the development of humanized anti-IL-13 antibodies and their variants thereof, which have equivalent or higher binding affinity and specificity to IL-13 relative to, e.g., an existing humanized anti-IL-13 antibody humanized from the same murine parental anti-IL-13 antibody. In some embodiments, a humanized anti-IL-13 antibody described herein has improved developability (e.g., higher yield during manufacturing relative to, for example, an existing humanized anti-IL-13 antibody humanized from the same murine parental anti-IL-13 antibody). Also provided are use of the anti-IL-13 antibodies and their variants in research, diagnostic / detection, and therapeutic applications.

[0063] Interleukin- 13 (IL- 13) is a cytokine primarily produced by immune cells, including type-2 CD4 T helper cells (Th2 cells), mast cells, and eosinophils. IL-13 can also be produced by non-immune cells, such as epithelial cells in the respiratory tract. It is also involved in the wound-healing process and, when dysregulated, facilitates fibrosis — the excess deposition of fibrous connective tissue — leading to decreased organ function and, if not corrected, organ failure.

[0064] IL- 13 is a mediator of allergic disease, in part via promotion of immunoglobulin E (IgE) production and / or recruitment / activation of granulocytes (e.g., eosinophils, mast cells, etc.). In some embodiments, IL- 13 induces or exacerbates inflammation (e.g., airway inflammation) due to increased IgE production and / or increased recruitment / activation of granulocytes (e.g., eosinophils, mast cells, etc.). In some embodiments, IL- 13 plays a role in some autoimmune conditions, such as inflammatory bowel disease (IBD). In some embodiments, IL-13 plays a role in skin barrier diseases (e.g., atopic dermatitis), for example, by increasing proinflammatory cytokines and / or reducing skin structural proteins that maintains skin integrity.#14704898vlTherefore, targeting IL-13 with antibodies that specifically bind IL-13 (e.g., an anti-IL-13 antibody provided herein) can relieve symptoms associated with IL- 13 production and dysregulation.

[0065] Accordingly, the present disclosure, at least in part, is based on the development of humanized anti-IL-13 antibodies that specifically bind IL- 13. Such antibodies have high affinity for IL- 13 and can neutralize IL- 13, thereby preventing it from exerting its inflammatory effects. Additionally, the antibodies provided herein have been optimized to improve producibility (e.g., increased efficiency of production and / or suitability for large-scale production). In some embodiments, an humanized anti-IL-13 antibody provided herein has improved expression, stability, solubility, and / or purification efficiency.I. Definitions

[0066] Administering: As used herein, the terms “administering” or “administration” means to provide an antibody or a composition thereof to a subject in a manner that is physiologically and / or pharmacologically useful (e.g., to treat a condition in the subject).

[0067] Affinity Matured Antibody: “Affinity Matured Antibody” is used herein to refer to an antibody with one or more alterations in one or more CDRs, which result in an improvement in the affinity (i.e., KD, kd, or ka) of the antibody for a target antigen compared to a parent antibody, which does not possess the alteration(s). Exemplary affinity matured antibodies will have nanomolar or even picomolar affinities for the target antigen. A variety of procedures for producing affinity matured antibodies are known in the art, including the screening of a combinatory antibody library that has been prepared using bio-display. For example, Marks et al., BioTechnology, 10: 779-783 (1992) describes affinity maturation by VH and VL domain shuffling. Random mutagenesis of CDR and / or framework residues is described by Barbas et al., Proc. Nat. Acad. Sci. USA, 91: 3809-3813 (1994); Schier et al., Gene, 169: 147-155 (1995); Yelton et al., J. Immunol., 155: 1994-2004 (1995); Jackson etal., J. Immunol., 154(7): 3310-3319 (1995); and Hawkins et al, J. Mol. Biol., 226: 889-896 (1992). Selective mutation at selective mutagenesis positions and at contact or hypermutation positions with an activityenhancing amino acid residue is described in U.S. Pat. No. 6,914,128 BL

[0068] Antibody: As used herein, the term “antibody” refers to a polypeptide that includes at least one immunoglobulin variable domain or at least one site, e.g., paratope, that specifically binds to an antigen. In some embodiments, an antibody is a full-length antibody. In some embodiments, an antibody is a chimeric antibody. In some embodiments, an antibody is a humanized antibody. However, in some embodiments, an antibody is a Fab fragment, a F(ab')2 fragment, a Fv fragment or a scFv fragment. In some embodiments, an antibody is a nanobody#14704898vlderived from a camelid antibody or a nanobody derived from shark antibody. In some embodiments, an antibody is a diabody. In some embodiments, an antibody comprises a framework having a human germline sequence. In another embodiment, an antibody comprises a heavy chain constant domain selected from the group consisting of IgG, IgGl, IgG2, IgG2A, IgG2B, IgG2C, IgG3, IgG4, IgAl, IgA2, IgD, IgM, and IgE constant domains. In some embodiments, an antibody comprises a heavy (H) chain variable region (abbreviated herein as VH), and / or a light (L) chain variable region (abbreviated herein as VL). In some embodiments, an antibody comprises a constant domain, e.g., an Fc region. An immunoglobulin constant domain refers to a heavy or light chain constant domain. Human IgG heavy chain and light chain constant domain amino acid sequences and their functional variations are known. With respect to the heavy chain, in some embodiments, the heavy chain of an antibody described herein can be an alpha (a), delta (A), epsilon (e), gamma (y) or mu (p) heavy chain. In some embodiments, the heavy chain of an antibody described herein can comprise a human alpha (a), delta (A), epsilon (e), gamma (y) or mu (p) heavy chain. In a particular embodiment, an antibody described herein comprises a human gamma 1 CHI, CH2, and / or CH3 domain. In some embodiments, the amino acid sequence of the constant region comprises the amino acid sequence of a human gamma (y) heavy chain constant region, such as any known in the art. Non-limiting examples of human constant region sequences have been described in the art, e.g., see U.S. Pat. No. 5,693,780 and Kabat E A et al., (1991) supra. In some embodiments, the VH domain comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or at least 99% identical to any of the heavy chain variable domains provided herein. In some embodiments, the VL domain comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or at least 99% identical to any of the light chain variable domains provided herein.

[0069] In some embodiments, an antibody is modified, e.g., modified via glycosylation, phosphorylation, sumoylation, and / or methylation. In some embodiments, an antibody is a glycosylated antibody, which is conjugated to one or more sugar or carbohydrate molecules. In some embodiments, the one or more sugar or carbohydrate molecule are conjugated to the antibody via N-glycosylation, O-glycosylation, C-glycosylation, glypiation (GPI anchor attachment), and / or phosphoglycosylation. In some embodiments, the one or more sugar or carbohydrate molecule are monosaccharides, disaccharides, oligosaccharides, or glycans. In some embodiments, the one or more sugar or carbohydrate molecule is a branched oligosaccharide or a branched glycan. In some embodiments, the one or more sugar or carbohydrate molecule includes a mannose unit, a glucose unit, an N-acetylglucosamine unit, or a phospholipid unit. In some embodiments, an antibody is a construct that comprises a#14704898vlpolypeptide comprising one or more antigen binding fragments of the disclosure linked to a linker polypeptide or an immunoglobulin constant domain. Linker polypeptides comprise two or more amino acid residues joined by peptide bonds and are used to link one or more antigen binding portions. Examples of linker polypeptides have been reported (see e.g., Holliger, P., et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak, R. J., et al. (1994) Structure 2:1121-1123). Still further, an antibody may be part of a larger immunoadhesion molecule, formed by covalent or noncovalent association of the antibody or antibody portion with one or more other proteins or peptides. Examples of such immunoadhesion molecules include use of the streptavidin core region to make a tetrameric scFv molecule (Kipriyanov, S. M., et al. (1995) Human Antibodies and Hybridomas 6:93-101) and use of a cysteine residue, a marker peptide and a C-terminal polyhistidine tag to make bivalent and biotinylated scFv molecules (Kipriyanov, S. M., et al. (1994) Mol. Immunol. 31:1047-1058).

[0070] Approximately: As used herein, the term “approximately” or “about,” as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In some embodiments, the term “approximately” or “about” refers to a range of values that fall within 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).

[0071] CDR: As used herein, the term "CDR" refers to the complementarity determining region within antibody variable sequences. A typical antibody molecule comprises a heavy chain variable region (VH) and a light chain variable region (VL), which are usually involved in antigen binding. The VH and VL regions can be further subdivided into regions of hypervariability, also known as “complementarity determining regions” (“CDR”), interspersed with regions that are more conserved, which are known as “framework regions” (“FR”). Each VH and VL is typically composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The extent of the framework region and CDRs can be precisely identified using methodology known in the art, for example, by the Kabat definition, the IMGT definition, the Chothia definition, the AbM definition, and / or the contact definition, all of which are well known in the art. See, e.g., Kabat, E.A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S.Department of Health and Human Services, NIH Publication No. 91-3242; IMGT®, the international ImMunoGeneTics information system® imgt.org, Lefranc, M.-P. et al., Nucleic Acids Res., 27:209-212 (1999); Ruiz, M. et al., Nucleic Acids Res., 28:219-221 (2000); Lefranc, M.-P., Nucleic Acids Res., 29:207-209 (2001); Lefranc, M.-P., Nucleic Acids Res., 31:307-310 #14704898vl(2003); Lefranc, M.-P. etal., In Silico Biol., 5, 0006 (2004) [[Epub]], 5:45-60 (2005); Lefranc, M.-P. et al., Nucleic Acids Res., 33:D593-597 (2005); Lefranc, M.-P. et al., Nucleic Acids Res., 37:D1006-1012 (2009); Lefranc, M.-P. etal., Nucleic Acids Res., 43:D413-422 (2015); Chothia etal., (1989) Nature 342:877; Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917, Al-lazikani et al (1997) J. Molec. Biol. 273:927-948; and Almagro, J. Mol. Recognit. 17:132-143 (2004). ee also hgmp.mrc.ac.uk and bioinf.org.uk / abs. As used herein, a CDR may refer to the CDR defined by any method known in the art. Two antibodies having the same CDR means that the two antibodies have the same amino acid sequence of that CDR as determined by the same method, for example, the IMGT definition.

[0072] In some embodiments, there are three CDRs in each of the variable regions of a heavy chain and a light chain, which are designated CDR1, CDR2 and CDR3, for each of the variable regions. The term "CDR set" as used herein refers to a group of three CDRs that occur in a single variable region capable of binding the antigen. The exact boundaries of these CDRs have been defined differently according to different systems. The system described by Kabat (Kabat et al., Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987) and (1991)) not only provides an unambiguous residue numbering system applicable to any variable region of an antibody, but also provides precise residue boundaries defining the three CDRs. These CDRs may be referred to as Kabat CDRs. Sub-portions of CDRs may be designated as LI, L2 and L3 or Hl, H2 and H3 where the "L" and the "H" designates the light chain and the heavy chains regions, respectively. These regions may be referred to as Chothia CDRs, which have boundaries that overlap with Kabat CDRs. Other boundaries defining CDRs overlapping with the Kabat CDRs have been described by Padlan (FASEB J. 9:133-139 (1995)) and MacCallum (J Mol Biol 262(5):732-45 (1996)). Still other CDR boundary definitions may not strictly follow one of the above systems, but will nonetheless overlap with the Kabat CDRs, although they may be shortened or lengthened in light of prediction or experimental findings that particular residues or groups of residues or even entire CDRs do not significantly impact antigen binding. The methods used herein may utilize CDRs defined according to any of these systems, although preferred embodiments use Kabat or Chothia defined CDRs.

[0073] In some embodiments, the CDRs of an antibody may have different amino acid sequences when different definition systems are used (e.g., the IMGT definition, the Kabat definition, or the Chothia definition). A definition system annotates each amino acid in a given antibody sequence (e.g., VH or VL sequence) with a number, and numbers corresponding to the heavy chain and light chain CDRs are provided in Table 1. The CDRs listed in Table 2 are defined in accordance with the Kabat definition. One skilled in the art is able to derive the CDR#14704898vlsequences using the different numbering systems for the anti-IL-13 antibodies provided in Table 2.Table 1. CDR Definitions1IMGT®, the internationalImMunoGeneTics information system®, imgt.org, Lefranc, M.-P. et al., Nucleic Acids Res., 27:209-212 (1999)2Kabat et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S.Department of Health and Human Services, NIH Publication No. 91-32423Chothia et al. , J. Mol. Biol. 196:901-917 (1987))

[0074] CDR-grafted antibody: The term "CDR-grafted antibody" refers to antibodies which comprise heavy and light chain variable region sequences from one species but in which the sequences of one or more of the CDR regions of VH and / or VL are replaced with CDR sequences of another species, such as antibodies having murine heavy and light chain variable regions in which one or more of the murine CDRs (e.g., CDR3) has been replaced with human CDR sequences.

[0075] Chimeric antibody: The term "chimeric antibody" refers to antibodies which comprise heavy and light chain variable region sequences from one species and constant region sequences from another species, such as antibodies having murine heavy and light chain variable regions linked to human constant regions.

[0076] Complementary: As used herein, the term “complementary” refers to the capacity for precise pairing between two nucleotides or two sets of nucleotides. In particular, complementary is a term that characterizes an extent of hydrogen bond pairing that brings about binding between two nucleotides or two sets of nucleotides. For example, if a base at one position of an oligonucleotide is capable of hydrogen bonding with a base at the corresponding position of a target nucleic acid (e.g., an mRNA), then the bases are considered to be complementary to each other at that position. Base pairings may include both canonical Watson-Crick base pairing and non-Watson-Crick base pairing (e.g., Wobble base pairing and Hoogsteen base pairing). For example, in some embodiments, for complementary base pairings, adenosine-type bases (A) are complementary to thymidine-type bases (T) or uracil-type bases (U), that cytosine-type bases (C) are complementary to guanosine-type bases (G), and that universal bases such as 3 -nitropyrrole or 5-nitroindole can hybridize to and are considered complementary to any A, C, U, or#14704898vlT. Inosine (I) has also been considered in the art to be a universal base and is considered complementary to any A, C, U or T.

[0077] Conservative amino acid substitution: As used herein, a “conservative amino acid substitution” refers to an amino acid substitution that does not alter the relative charge or size characteristics of the protein in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g., Molecular Cloning: A Laboratory Manual, J. Sambrook, et al., eds., Fourth Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2012, or Current Protocols in Molecular Biology, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

[0078] Cross-reactive: As used herein and in the context of a targeting agent (e.g., antibody), the term “cross-reactive,” refers to a property of the agent being capable of specifically binding to more than one antigen of a similar type or class (e.g., antigens of multiple homologs, paralogs, or orthologs) with similar affinity or avidity. For example, in some embodiments, an antibody that is cross-reactive against human and non-human primate antigens of a similar type or class (e.g., a human IL-13 and non-human primate IL-13) is capable of binding to the human antigen and non-human primate antigens with a similar affinity or avidity. In some embodiments, an antibody is cross-reactive against a human antigen and a rodent antigen of a similar type or class. In some embodiments, an antibody is cross -reactive against a rodent antigen and a non-human primate antigen of a similar type or class. In some embodiments, an antibody is cross -reactive against a human antigen, a non-human primate antigen, and a rodent antigen of a similar type or class.

[0079] Effective Amount: As used herein, “an effective amount” refers to the amount of each active agent (e.g., anti-IL-13 antibody) required to confer therapeutic effect on the subject, either alone or in combination with one or more other active agents. In some embodiments, the therapeutic effect is reduced IL- 13 level or activity, and / or alleviated disease conditions (e.g., allergic disease, asthma, or autoimmune disorders).

[0080] Framework: As used herein, the term "framework" (FW) or "framework sequence" refers to the remaining sequences of a variable region minus the CDRs. Because the exact definition of a CDR sequence can be determined by different systems, the meaning of a framework sequence is subject to correspondingly different interpretations. The six CDRs (CDR-Ll, CDR-L2, and CDR-L3 of light chain and CDR-H1, CDR-H2, and CDR-H3 of heavy chain) also divide the framework regions on the light chain and the heavy chain into four sub-regions #14704898vl(FW1, FW2, FW3 and FW4) on each chain, in which CDR1 is positioned between FW1 and FW2, CDR2 between FW2 and FW3, and CDR3 between FW3 and FW4. Without specifying the particular sub-regions as FW1, FW2, FW3 or FW4, a framework region, as referred by others, represents the combined FWs within the variable region of a single, naturally occurring immunoglobulin chain. As used herein, a FW represents one of the four sub-regions, and FWs represents two or more of the four sub-regions constituting a framework region. Human heavy chain and light chain acceptor sequences are known in the art. In one embodiment, the acceptor sequences known in the art may be used in the antibodies disclosed herein.

[0081] Human antibody: The term "human antibody", as used herein, is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human antibodies of the disclosure may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or sitespecific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs and in particular CDR3. However, the term "human antibody", as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.

[0082] Humanized antibody: The term "humanized antibody" refers to antibodies which comprise heavy and light chain variable domain sequences from a non-human species (e.g., a mouse) but in which at least a portion of the VH and / or VL sequence has been altered to be more "human-like", i.e., more similar to human germline variable sequences. One type of humanized antibody is a CDR-grafted antibody, in which CDR (e.g., nonhuman CDR) sequences are introduced into human VH and VL sequences (e.g., combined with human VH and VL framework regions) to replace the corresponding nonhuman CDR sequences. In one embodiment, humanized anti-IL-13 antibodies and antigen binding portions are provided. Such antibodies may be generated by obtaining murine anti-IL-13 monoclonal antibodies using traditional hybridoma technology followed by humanization using in vitro genetic engineering, such as those disclosed in Kasaian et al. PCT publication No. WO 2005 / 123126 A2.

[0083] Humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. In some embodiments, Fv framework region (FW) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, the humanized antibody may comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences, but are included to further refine and optimize antibody performance. In general, the humanized antibody will #14704898vlcomprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FW regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region or domain (Fc), typically that of a human immunoglobulin. Antibodies may have Fc regions modified as described in WO 99 / 58572. Other forms of humanized antibodies have one or more CDRs (one, two, three, four, five, six) which are altered with respect to the original antibody, which are also termed one or more CDRs derived from one or more CDRs from the original antibody. Humanized antibodies may also involve affinity matured antibodies.

[0084] In some embodiments, humanization is achieved by grafting the CDRs (e.g., as shown in Table 2) into the human variable domains (e.g., IGKV1-NL1*O1 and IGHV1-3*O1 human variable domain). In some embodiments, an anti-IL-13 antibody of the present disclosure is a humanized antibody comprising one or more amino acid substitutions (e.g., in the VH framework region) as compared with any one of the VHs listed in Table 2, and / or one or more amino acid substitutions (e.g., in the VL framework region) as compared with any one of the VLs listed in Table 2.

[0085] In some embodiments, humanization of a non-humanized antibody is achieved by grafting CDRs of the non-humanized antibody into HC and / or LC framework regions corresponding to any one of the framework sets listed in Tables 3a-3b (e.g., by grafting CDRs of the non-humanized antibody into any one of the HC FW sets listed in Table 3a and / or one of the LC FW sets listed in Table 3b).

[0086] Interleukin- 13: Interleukin- 13 (IL-13) is a cytokine produced by both immune cells (e.g., type-2 CD4 T helper cells, eosinophils, and mast cells) and non-immune cells (e.g., epithelial cells in the respiratory tract). IL- 13 can be beneficial, e.g., during parasitic infection, but when dysregulated can induce or exacerbate inflammation and diseases associated with inflammation, such as allergic disease, asthma, and some autoimmune disorders (e.g., inflammatory bowel disease, IBD). IL-13, among other effector functions, induces mucus production, activates eosinophils, and facilitates fibrosis, all of which can promote disease states when IL-13 is produced aberrantly and / or in excess. IL-13 mediates allergic disease, in part via promotion of immunoglobulin E (IgE) production and / or recruitment / activation of granulocytes (e.g., eosinophils, mast cells, etc.). In some embodiments, IL- 13 induces or exacerbate inflammation (e.g., airway inflammation) due to increased IgE production and / or increased recruitment / activation of granulocytes (e.g., eosinophils, mast cells, etc.). In some embodiments, IL- 13 plays a role in some autoimmune conditions, such as inflammatory bowel disease (IBD). In some embodiments, IL- 13 plays a role in skin barrier diseases (e.g., atopic dermatitis), for #14704898vlexample, by increasing proinflammatory cytokines and / or reducing skin structural proteins that maintains skin integrity.

[0087] Isolated antibody: An "isolated antibody", as used herein, is intended to refer to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds IL- 13 is substantially free of antibodies that specifically bind antigens other than IL-13). An isolated antibody that specifically binds IL-13 may, however, have cross -reactivity to other antigens. Moreover, an isolated antibody may be substantially free of other cellular material and / or chemicals.

[0088] Kabat numbering: The terms “Kabat numbering”, “Kabat definitions” and “Kabat labeling” are used interchangeably herein. These terms, which are recognized in the art, refer to a system of numbering amino acid residues which are more variable (i.e. hypervariable) than other amino acid residues in the heavy and light chain variable regions of an antibody, or an antigen binding portion thereof (Kabat et al. (1971) Ann. NY Acad, Sci. 190:382-391 and, Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). For the heavy chain variable region, the hypervariable region ranges from amino acid positions 31 to 35 for CDR1, amino acid positions 50 to 65 for CDR2, and amino acid positions 95 to 102 for CDR3. For the light chain variable region, the hypervariable region ranges from amino acid positions 24 to 34 for CDR1, amino acid positions 50 to 56 for CDR2, and amino acid positions 89 to 97 for CDR3.

[0089] Recombinant antibody: The term "recombinant antibody", as used herein, is intended to include all antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell (described in more details in this disclosure), including, for example, antibodies isolated from a recombinant, combinatorial human antibody library (Hoogenboom H. R., (1997) TIB Tech. 15:62-70; Azzazy H., and Highsmith W. E., (2002) Clin. Biochem. 35:425-445; Gavilondo J. V., and Larrick J. W. (2002) BioTechniques 29:128-145; Hoogenboom H., and Chames P. (2000) Immunology Today 21:371-378), antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see e.g., Taylor, L. D., et al. (1992) Nucl. Acids Res. 20:6287-6295; Kellermann S-A., and Green L. L. (2002) Current Opinion in Biotechnology 13:593-597; Little M. et al (2000) Immunology Today 21:364-370) or antibodies prepared, expressed, created or isolated by any other means that involves splicing of human immunoglobulin gene sequences to other DNA sequences. In some embodiments, recombinant human antibodies are provided herein. In some embodiments, such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. In some embodiments, however, such recombinant human antibodies are subjected to #14704898vlin vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire in vivo. One embodiment of the disclosure provides fully human antibodies capable of binding human IL-13 which can be generated using techniques well known in the art, such as, but not limited to, using human Ig phage libraries such as those disclosed in Jermutus et al., PCT publication No. WO 2005 / 007699 A2.

[0090] Selective: As used herein, the term “selective” or “selectively” refers to the ability of a molecule to produce an effect (e.g., inhibit, antagonize, agonize, etc.) in relation to its target molecule compared to a reference molecule. For example, a molecule that selectively inhibits its target molecule means that this molecule is capable of inhibiting its target molecule with a degree that is distinguishable from a reference molecule in an inhibition assay or other inhibitory context. For example, with respect to an inhibitor, the term, “selectively inhibits”, refers to the ability of the inhibitor to inhibit its target molecule with a degree that is distinguishable from a reference molecule that is not substantially inhibited in an inhibition assay, e.g., to an extent that permit selective inhibition of the target molecule, as described herein. Once the reaction is terminated, the signal produced by inhibiting the target molecule can be measured. The half maximal inhibitor concentration for the target molecule and the reference molecule can be calculated. In some embodiments, a molecule described herein selectively binds to a target molecule. In some embodiments, a molecule described herein selectively inhibits a target molecule. In some embodiments, a molecule described herein selectively antagonized a target molecule. In some embodiments, a molecule described herein selectively neutralizes to a target molecule.

[0091] Specifically binds: As used herein, the term “specifically binds” refers to the ability of a molecule to bind to a binding partner with a degree of affinity or avidity that enables the molecule to be used to distinguish the binding partner from an appropriate control in a binding assay or other binding context. With respect to an antibody, the term, “specifically binds,” refers to the ability of the antibody to bind to a specific antigen with a degree of affinity or avidity, compared with an appropriate reference antigen or antigens, that enables the antibody to be used to distinguish the specific antigen from others, as described herein. In some embodiments, an antibody specifically binds to a target if the antibody has a KD for binding the target of at least about 10’4M, 10’5M, 10’6M, 10’7M, 10’8M, 10’9M, 10’10M, 10’11M, 10’12M, 10’13M, or less. In some embodiments, an antibody specifically binds IL-13.#14704898vl

[0092] Subject: As used herein, the term “subject” refers to a mammal. In some embodiments, a subject is non-human primate, or rodent. In some embodiments, a subject is a human. In some embodiments, a subject is a patient, e.g., a human patient that has or is suspected of having a disease. In some embodiments, the subject is a human patient who has or is suspected of having an inflammatory disease (e.g., allergic disease, asthma, or autoimmune disease) and / or one or more conditions arising as a result of IL- 13 production.

[0093] Treatment: As used herein, the term “treating” or “treatment” refers to the application or administration of a composition including one or more active agents (e.g., anti-IL-13 antibodies) to a subject, who has a target disease or disorder, a symptom of the disease / disorder, or a predisposition toward the disease / disorder, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect the disorder, the symptom of the disease, or the predisposition toward the disease or disorder. Alleviating a target disease / disorder includes delaying or preventing the development or progression of the disease, or reducing disease severity.II. Anti-IL-13 Antibodies

[0094] In some embodiments, the anti-IL-13 antibody is an antibody specific for IL- 13.Provided herein, in some aspects, are antibodies that bind to human IL- 13 with high specificity and affinity. In some embodiments, the anti-IL-13 antibody described herein specifically binds to any extracellular epitope of a IL- 13 or an epitope that becomes exposed to an antibody. In some embodiments, anti-IL-13 antibodies provided herein bind specifically to IL- 13 from human, and / or non-human primates. In some embodiments, anti-IL-13 antibodies provided herein bind to human IL- 13. In some embodiments, the anti-IL-13 antibody described herein binds to an amino acid segment of a human IL- 13.

[0095] In some embodiments, the anti-IL-13 antibody described herein specifically binds to an epitope on human IL-13. Human IL-13 is encoded by the IL13 gene, located on chromosome 5, and is 146 amino acids in length. The IL- 13 protein-coding and amino acid sequences have been well-characterized (see UniProt ID P35225).

[0096] In some embodiments, the anti-IL-13 antibody described herein may bind to a fragment of a human IL- 13. The fragment of IL- 13 may be between about 5 and about 150 amino acids, between about 10 and about 125 amino acids, between about 50 and about 100 amino acids, between about 75 and about 150 amino acids, between about 100 and about 150 amino acids, or between about 125 and about 150 amino acids. The fragment may comprise a contiguous number of amino acids from IL- 13. In some embodiments, an anti-IL-13 antibody described herein binds#14704898vlto a similar epitope or an overlapping epitope or the same epitope as lebrikizumab, or otherwise competes for binding IL- 13 as compared to lebrikizumab.

[0097] In some embodiments, an anti-IL-13 antibody specifically binds an IL-13 (e.g., a human or non-human primate IL-13) with binding affinity (e.g., as indicated by KD) of at least about 10’4M, 10’5M, 10’6M, 10’7M, 10’8M, 10’9M, IO’10M, 10’11M, 10’12M, 10’13M, or less. In some embodiments, an anti-IL-13 antibody specifically binds an IL-13 (e.g., a human or non-human primate IL- 13) with binding affinity (e.g., as indicated by KD) of at about 1011M to about IO’13M. In some embodiments, an anti-IL-13 antibody specifically binds an IL- 13 (e.g., a human or non-human primate IL-13) with binding affinity (e.g., as indicated by KD) of about 10’12M. For example, the anti-IL13 antibodies of the present disclosure can bind to a IL- 13 protein (e.g., human IL- 13) with an affinity between 5 pM and 500 nM, e.g., between 50 pM and 100 nM, e.g., between 500 pM and 50 nM. The disclosure also includes antibodies that compete with any of the antibodies described herein for binding to a IL-13 protein (e.g., human IL-13) and that have an affinity of 100 nM or lower (e.g., 80 nM or lower, 50 nM or lower, 20 nM or lower, 10 nM or lower, 500 pM or lower, 50 pM or lower, or 5 pM or lower). The affinity and binding kinetics of the anti-IL-13 antibody can be tested using any suitable method including but not limited to biosensor technology (e.g., OCTET or BIACORE). In some embodiments, the anti-IL-13 antibodies described herein binds to IL- 13 with a KD of sub-nanomolar and / or sub-picomolar range.

[0098] Binding affinity (or binding specificity) can be determined by a variety of methods including equilibrium dialysis, equilibrium binding, gel filtration, ELISA, surface plasmon resonance (SPR), fluorescence activated cell sorting (FACS) or spectroscopy (e.g., using a fluorescence assay). Exemplary conditions for evaluating binding affinity are in HBS-P buffer (10 mM HEPES pH7.4, 150 mM NaCl, 0.005% (v / v) surfactant P20) and PBS buffer (lOmM PO4-3, 137mM NaCl, and 2.7mM KC1). These techniques can be used to measure the concentration of bound proteins as a function of target protein concentration. The concentration of bound protein ([[Bound]]) is generally related to the concentration of free target protein ([[Free]]) by the following equation:[[Bound]] = [[Free]] / (Kd+[[Free]])

[0099] It is not always necessary to make an exact determination of KA, though, since sometimes it is sufficient to obtain a quantitative measurement of affinity, e.g., determined using a method such as ELISA or FACS analysis, is proportional to KA, and thus can be used for comparisons, such as determining whether a higher affinity is, e.g., 2-fold higher, to obtain a qualitative measurement of affinity, or to obtain an inference of affinity, e.g., by activity in a functional assay, e.g., an in vitro or in vivo assay.#14704898vl[000100] In some embodiments, an anti-IL-13 antibody described herein is a humanized antibody from a murine parental antibody (e.g., a murine parental antibody comprising a VH that comprises the amino acid sequence of SEQ ID NO: 14 and a VL that comprises the amino acid sequence of SEQ ID NO: 59. In some embodiments, the CDRs from a murine anti-IL-13 antibody VH (e.g., a VH comprising the amino acid sequence of SEQ ID NO: 14) can be grafted into framework sequences from human germline immunoglobulin genes to obtain a humanized anti-IL-13 antibody heavy chain variable domain. In some embodiments, the CDRs of a heavy chain variable domain of a murine anti-IL-13 antibody (e.g., a VH comprising the amino acid sequence of SEQ ID NO: 14) can be grafted into framework sequences from human germline immunoglobulin heavy chain genes to obtain a humanized anti-IL-13 antibody heavy chain variable domain. In some embodiments, the CDRs from a light chain variable domain of a murine anti-IL-13 antibody (e.g., a VL comprising the amino acid sequence of SEQ ID NO: 14) can be grafted into framework sequences from human germline immunoglobulin light chain genes to obtain a humanized anti-IL-13 antibody light chain variable domain. In some embodiments, an anti-IL-13 antibody is obtained by combining a humanized VH from the set of VH obtained from the humanization process and a humanized VL from the set of VL obtained from the humanization process. In some embodiments, one or more point mutations to a humanized VH and / or humanized VL are performed to improve property and / or function of the antibody (e.g., remove sequence liability, etc.) while maintaining or improving the binding profile to IL- 13 (e.g., human IL- 13) relative to existing humanized anti-IL-13 antibody (e.g., humanized anti-IL-13 antibody obtained from the same murine parental antibody such as comparator #1 and / or comparator #2). In some embodiments, an anti-IL-13 antibody described herein has improved binding affinity to IL-13 (e.g., human IL-13). In some embodiments, an anti-IL-13 antibody described herein shows improved developability (e.g., increased production titer) relative to an existing humanized anti-IL-13 antibody (e.g., humanized anti-IL-13 antibody obtained from the same murine parental antibody such as comparator #1 and / or comparator #2). In some embodiments, certain combination of a humanized VH and a humanized VL yields an anti-IL-13 antibody that shows improved properties (e.g., increased production titer) relative to other combinations of humanized VH and humanized VL. In some embodiments, certain combination of a humanized VH and a humanized VL yields an anti-IL-13 antibody that shows improved properties (e.g., increased production titer) relative to relative to an existing humanized anti-IL-13 antibody (e.g., humanized anti-IL-13 antibody obtained from the same murine parental antibody such as comparator #1 and / or comparator #2).[000101] Illustrative, non-limiting examples of anti-IL-13 antibodies are provided in Table 2.#14704898vlTable 2. Illustrative Anti-IL-13 Antibodies#14704898vl#14704898vl#14704898vl[000102] In some embodiments, the anti-IL-13 antibodies of the present disclosure comprises one or more of the HC CDRs (e.g., HC CDR1, HC CDR2, or HC CDR3) amino acid sequences from any one of the anti-IL-13 antibody antibodies selected from Table 2. In some embodiments, the anti-IL13 antibodies of the present disclosure comprise the HC CDR1, HC CDR2, and HC CDR3 as provided for any one of the antibodies elected from Table 2. In some embodiments, the anti-IL-13 antibodies of the present disclosure comprises one or more of the LC CDRs e.g., LC CDR1, LC CDR2, or LC CDR3) amino acid sequences from any one of the anti-IL-13 antibodies selected from Table 2. In some embodiments, the anti-IL-13 antibodies of the present disclosure comprise the LC CDR1, LC CDR2, and LC CDR3 s provided for any one of the anti-IL-13 antibodies selected from Table 2.[000103] In some embodiments, the anti-IL-13 antibodies of the present disclosure comprises the HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3 as provided for any one of the anti-IL-13 antibodies selected from Table 2. In some embodiments, antibody heavy and light chain CDR3 domains may play a particularly important role in the binding specificity / affinity of an antibody for an antigen. Accordingly, the anti-IL-13 antibodies of the disclosure may include at least the heavy and / or light chain CDR3s of any one of the anti-IL-13 antibodies selected from Table 2.[000104] In some embodiments, an isolated anti-IL-13 antibody of the present disclosure comprises a heavy chain variable region that comprises a heavy chain CDR1 (HC CDR1), a heavy chain CDR2 (HC CDR2), and a heavy chain CDR3 (HC CDR3) selected from Table 2. In some embodiments, the isolated anti-IL-13 antibody comprises a light chain variable region that comprises a light chain CDR1 (LC CDR1), a light chain CDR2 (LC CDR2), and a light chain CDR3 (LC CDR3) selected from Table 2.[000105] Also within the scope of the present disclosure are functional variants of any of the exemplary anti-IL-13 antibodies as disclosed herein. A functional variant may contain one or more amino acid residue variations in the VH and / or VL, or in one or more of the HC CDRs and / or one or more of the LC CDRs as relative to the reference antibody, while retaining substantially similar binding and biological activities (e.g., substantially similar binding affinity, binding specificity, inhibitory activity, anti-inflammatory activity, or a combination thereof) as the reference antibody.#14704898vl[000106] In some embodiments, any of the anti-IL-13 antibodies of the disclosure have one or more CDRs (e.g., HC CDR or LC CDR) sequences substantially similar to any of the HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and / or LC CDR3 sequences from one of the anti-IL-13 antibodies selected from Table 2. In some embodiments, the position of one or more CDRs along the VH (e.g., HC CDR1, HC CDR2, or HC CDR3) and / or VL (e.g., LC CDR1, LC CDR2, or LC CDR3) region of an antibody described herein can vary by one, two, three, four, five, or six amino acid positions so long as immunospecific binding to IL-13 (e.g., human IL-13) is maintained (e.g., substantially maintained, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% of the binding of the original antibody from which it is derived). For example, in some embodiments, the position defining a CDR of any antibody described herein can vary by shifting the N-terminal and / or C-terminal boundary of the CDR by one, two, three, four, five, or six amino acids, relative to the CDR position of any one of the antibodies described herein, so long as immunospecific binding to IL-13 (e.g., human IL-13) is maintained (e.g., substantially maintained, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% of the binding of the original antibody from which it is derived). In another embodiment, the length of one or more CDRs along the VH (e.g., HC CDR1, HC CDR2, or HC CDR3) and / or VL (e.g., LC CDR1, LC CDR2, or LC CDR3) region of an antibody described herein can vary (e.g., be shorter or longer) by one, two, three, four, five, or more amino acids, so long as immuno specific binding to IL-13 (e.g., human IL-13) is maintained (e.g., substantially maintained, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% of the binding of the original antibody from which it is derived).[000107] Accordingly, in some embodiments, a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and / or LC CDR3 described herein may be one, two, three, four, five or more amino acids shorter than one or more of the CDRs described herein (e.g., CDRS from any of the anti-IL-13 antibodies selected from Table 2) so long as immunospecific binding to IL-13 (e.g., human IL-13) is maintained (e.g., substantially maintained, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% relative to the binding of the original antibody from which it is derived). In some embodiments, a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and / or LC CDR3 described herein may be one, two, three, four, five or more amino acids longer than one or more of the CDRs described herein (e.g., CDRS from any of the anti-IL-13 antibodies selected from Table 2) so long as immuno specific binding to IL-13 (e.g., human IL- 13) is maintained (e.g., substantially maintained, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% relative to the binding of the original antibody from which it is derived). In some embodiments, the amino portion of a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and / or LC CDR3 described herein can be extended #14704898vlby one, two, three, four, five or more amino acids compared to one or more of the CDRs described herein (e.g., CDRS from any of the anti-IL-13 antibodies 2) so long as immuno specific binding to IL- 13 (e.g., human IL- 13) is maintained (e.g., substantially maintained, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% relative to the binding of the original antibody from which it is derived). In some embodiments, the carboxy portion of a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and / or LC CDR3 described herein can be extended by one, two, three, four, five or more amino acids compared to one or more of the CDRs described herein (e.g., CDRS from any of the anti-IL-13 antibodies 2) so long as immunospecific binding to IL- 13 (e.g., human IL- 13) is maintained (e.g., substantially maintained, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% relative to the binding of the original antibody from which it is derived). In some embodiments, the amino portion of a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and / or LC CDR3 described herein can be shortened by one, two, three, four, five or more amino acids compared to one or more of the CDRs described herein (e.g., CDRS from any of the anti-IL-13 antibodies selected from Table 2) so long as immunospecific binding to IL-13 (e.g., human IL-13) is maintained (e.g., substantially maintained, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% relative to the binding of the original antibody from which it is derived). In some embodiments, the carboxy portion of a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and / or LC CDR3 described herein can be shortened by one, two, three, four, five or more amino acids compared to one or more of the CDRs described herein (e.g., CDRS from any of the anti-IL-13 antibodies 2) so long as immuno specific binding to IL-13 (e.g., human IL-13) is maintained (e.g., substantially maintained, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% relative to the binding of the original antibody from which it is derived). Any method can be used to ascertain whether immuno specific binding to IL-13 (e.g., human IL-13) is maintained, for example, using binding assays and conditions described in the art.[000108] In some examples, any of the anti-IL-13 antibodies of the disclosure have one or more CDR (e.g., HC CDR or LC CDR) sequences substantially similar to any one of the anti-IL-13 antibodies 2. For example, the antibodies may include one or more CDR sequence(s) from any of the anti-IL-13 antibodies selected from Table 2 containing up to 5, 4, 3, 2, or 1 amino acid residue variations as compared to the corresponding CDR region in any one of the CDRs provided herein (e.g., CDRs from any of the anti-IL-13 antibodies selected from Table 2) so long as immuno specific binding to IL-13 (e.g., human IL-13) is maintained (e.g., substantially maintained, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% relative to the binding of the original antibody from which it is derived). In some #14704898vlembodiments, any of the amino acid variations in any of the CDRs provided herein may be conservative variations. Conservative variations can be introduced into the CDRs at positions where the residues are not likely to be involved in interacting with a IL-13 protein (e.g., a human IL-13 protein), for example, as determined based on a crystal structure. Some aspects of the disclosure provide anti-IL-13 antibodies that comprise one or more of the heavy chain variable (VH) and / or light chain variable (VL) domains provided herein. In some embodiments, any of the VH domains provided herein include one or more of the HC CDR sequences (e.g., HC CDR1, HC CDR2, and HC CDR3) provided herein, for example, any of the HC CDR sequences provided in any one of the anti-IL-13 antibodies selected from Table 2. In some embodiments, any of the VL domains provided herein include one or more of the LC CDR sequences (e.g., LC CDR1, LC CDR2, and LC CDR3) provided herein, for example, any of the LC CDR sequences provided in any one of the anti-IL-13 antibodies selected from Table 2.[000109] In some embodiments, the anti-IL-13 antibodies of the disclosure include any antibody that includes a heavy chain variable domain and / or a light chain variable domain of any one of the anti-IL-13 antibodies selected from Table 2, and variants thereof. In some embodiments, anti-IL-13 antibodies of the disclosure include any antibody that includes the heavy chain variable and light chain variable pairs of any anti-IL-13 antibodies selected from Table 2.[000110] Aspects of the disclosure provide anti-IL-13 antibodies having a heavy chain variable (VH) and / or a light chain variable (VL) domain amino acid sequence homologous to any of those described herein. In some embodiments, the anti-IL-13 antibody comprises a heavy chain variable sequence or a light chain variable sequence that is at least 75% (e.g., 80%, 85%, 90%, 95%, 98%, or 99%) identical to the heavy chain variable sequence and / or any light chain variable sequence of any one of the anti-IL-13 antibodies selected from Table 2. In some embodiments, the homologous heavy chain variable and / or a light chain variable amino acid sequences do not vary within any of the CDR sequences provided herein. For example, in some embodiments, the degree of sequence variation (e.g., 75%, 80%, 85%, 90%, 95%, 98%, or 99%) may occur within a heavy chain variable and / or a light chain variable sequence excluding any of the CDR sequences provided herein. In some embodiments, any of the anti-IL-13 antibodies provided herein comprise a heavy chain variable sequence that comprises a framework sequence that is at least 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical to the framework sequence of the VH domains of any one of the anti-IL-13 antibody selected from Table 2 and a light chain variable sequence that comprises a framework sequence that is at least 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical to the framework sequence of the VL domains of any one of the anti-IL-13 antibodies selected from Table 2.#14704898vl[000111] In some embodiments, the anti-IL-13 antibody of the present disclosure is a humanized antibody (e.g., a humanized variant containing one or more CDRs of Table 2). In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, a HC CDR3, a LC CDR1, a LC CDR2, and a LC CDR3 that are the same as the HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3 shown in Table 2, and comprises a humanized heavy chain variable region and / or a humanized light chain variable region.[000112] In some embodiments, the anti-IL-13 antibody of the present disclosure is a humanized antibody comprising a VH containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VH of any of the anti-IL-13 antibodies listed in Table 2. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure is a humanized antibody comprising a VL containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VL of any one of the anti-IL-13 antibodies listed in Table 2.[000113] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 19. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 63.[000114] In some embodiments, according to the Kabat definition system, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 2, a HC CDR2 having the amino acid sequence of SEQ ID NO: 20, a HC CDR3 having the amino acid sequence of SEQ ID NO: 4, a LC CDR1 having the amino acid sequence of SEQ ID NO: 44, a LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000115] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 2, HC CDR2 having the amino acid sequence of SEQ ID NO: 20, and HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 44, LC CDR2 having the amino acid #14704898vlsequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000116] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% {e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 2, HC CDR2 having the amino acid sequence of SEQ ID NO: 20, and HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% {e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 44, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000117] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations {e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 2; a HC CDR2 having no more than 3 amino acid variations e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 20; and / or a HC CDR3 having no more than 3 amino acid variations {e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations {e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 44; a LC CDR2 having no more than 3 amino acid variations {e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of SEQ ID NO: 45; and / or a LC CDR3 having no more than 3 amino acid variations {e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000118] In some embodiments, according to the Chothia definition system, an anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 82, a HC CDR2 having the amino acid sequence of SEQ ID NO: 83, a HC CDR3 having the amino acid sequence of SEQ ID NO: 84, a LC CDR1 having the amino acid sequence of SEQ ID NO: 44, a LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000119] In some embodiments, an anti-IL-13 antibody of the present disclosure comprises a HC #14704898vlCDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 82, HC CDR2 having the amino acid sequence of SEQ ID NO: 83, and HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 44, LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000120] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 82, HC CDR2 having the amino acid sequence of SEQ ID NO: 83, and HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, an anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 44, LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000121] In some embodiments, an anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 82; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 83; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, an anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 44; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of SEQ ID NO: 89; and / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence #14704898vlof SEQ ID NO: 90.[000122] In some embodiments, according to the IMGT definition system, an anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 85, a HC CDR2 having the amino acid sequence of SEQ ID NO: 86, a HC CDR3 having the amino acid sequence of SEQ ID NO: 87 a LC CDR1 having the amino acid sequence of SEQ ID NO: 91, a LC CDR2 having the amino acid sequence of LAS, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000123] In some embodiments, an anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 85, HC CDR2 having the amino acid sequence of SEQ ID NO: 86, and HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, an anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 91, LC CDR2 having the amino acid sequence of LAS, and LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000124] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 85, HC CDR2 having the amino acid sequence of SEQ ID NO: 86, and HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, an anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 91, LC CDR2 having the amino acid sequence of LAS, and LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000125] In some embodiments, an anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 85; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 86; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 #14704898vlamino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, an anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 91; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of LAS; and / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000126] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 19. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL comprising the amino acid sequence of SEQ ID NO: 63.[000127] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VH as set forth in SEQ ID NO: 19. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VL as set forth in SEQ ID NO: 63. In some embodiments, the number of amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) may occur within a VH of SEQ ID NO: 19 and / or a VL of SEQ ID NO: 63 excluding any of the CDR sequences therein. In some embodiments, an anti-IL-13 antibodies provided herein comprise a heavy chain variable sequence that comprises a framework sequence that that contains no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation to the framework sequence of a VH of SEQ ID NO: 19, and / or a light chain variable sequence that comprises a framework sequence that that contains no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation to the framework sequence of a VL of SEQ ID NO: 63.[000128] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH comprising an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VH as set forth in SEQ ID NO: 19. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL comprising an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least #14704898vl90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VL as set forth in SEQ ID NO: 63. In some embodiments, the degree of sequence variation (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) may occur within a VH of SEQ ID NO: 19, and / or a VL of SEQ ID NO: 63 excluding any of the CDR sequences therein. In some embodiments, an anti-IL-13 antibody provided herein comprise a heavy chain variable sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the framework sequence of a VH of SEQ ID NO: 19, and / or a light chain variable sequence that comprises a framework sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the framework sequence of a VL of SEQ ID NO: 63.[000129] In some embodiments, according to the Kabat definition system, the anti-IL-13 antibody of the present disclosure comprises a HC FW1 having the amino acid sequence of SEQ ID NO: 21, a HC FW2 having the amino acid sequence of SEQ ID NO: 22, a HC FW3 having the amino acid sequence of SEQ ID NO: 23, a HC FW4 having the amino acid sequence of SEQ ID NO: 8, a LC FW1 having the amino acid sequence of SEQ ID NO: 47, a LC FW2 having the amino acid sequence of SEQ ID NO: 48, a LC FW3 having the amino acid sequence of SEQ ID NO: 64, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000130] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC FW1, a HC FW2, a HC FW3, and a HC FW4, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC FW1 having the amino acid sequence of SEQ ID NO: 21, HC FW2 having the amino acid sequence of SEQ ID NO: 22, HC FW3 having the amino acid sequence of SEQ ID NO: 23, and HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC FW1, a LC FW2, a LC FW3, and a LC FW4, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC FW1 having the amino acid sequence of SEQ ID NO: 47, LC FW2 having the amino acid sequence of SEQ ID NO: 48, LC FW3 having the amino acid sequence of SEQ ID NO: 64, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000131] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC FW1, a HC FW2, a HC FW3, and a HC FW4 that collectively are at least 80% (e.g., at least #14704898vl80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC FW1 having the amino acid sequence of SEQ ID NO: 21, HC FW2 having the amino acid sequence of SEQ ID NO: 22, HC FW3 having the amino acid sequence of SEQ ID NO: 23, and HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC FW1, a LC FW2, a LC FW3, and a LC FW4 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC FW1 having the amino acid sequence of SEQ ID NO: 47, LC FW2 having the amino acid sequence of SEQ ID NO: 48, LC FW3 having the amino acid sequence of SEQ ID NO: 64, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000132] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC FW1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW1 having the amino acid sequence of SEQ ID NO: 21; a HC FW2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW2 having the amino acid sequence of SEQ ID NO: 22; a HC FW3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW3 having the amino acid sequence of SEQ ID NO: 23; and / or a HC FW4 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC FW1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW1 having the amino acid sequence of SEQ ID NO: 47; a LC FW2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW2 having the amino acid sequence of SEQ ID NO: 48; a LC FW3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW3 having the amino acid sequence of SEQ ID NO: 64; and / or a LC FW4 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000133] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 24. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain #14704898vlhaving the amino acid sequence of SEQ ID NO: 66.[000134] In some embodiments, according to the Kabat definition system, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 2, a HC CDR2 having the amino acid sequence of SEQ ID NO: 3, a HC CDR3 having the amino acid sequence of SEQ ID NO: 4, a LC CDR1 having the amino acid sequence of SEQ ID NO: 44, a LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000135] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 2, HC CDR2 having the amino acid sequence of SEQ ID NO: 3, and HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 44, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000136] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 2, HC CDR2 having the amino acid sequence of SEQ ID NO: 3, and HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 44, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000137] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 2; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 3; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 #14704898vlamino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 44; a LC CDR2 having no more than 3 amino acid variations e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of SEQ ID NO: 45; and / or a LC CDR3 having no more than 3 amino acid variations e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000138] In some embodiments, according to the Chothia definition system, an anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 98, a HC CDR2 having the amino acid sequence of SEQ ID NO: 83, a HC CDR3 having the amino acid sequence of SEQ ID NO: 84 a LC CDR1 having the amino acid sequence of SEQ ID NO: 44, a LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000139] In some embodiments, an anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 98, HC CDR2 having the amino acid sequence of SEQ ID NO: 83, and HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 44, LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000140] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 98, HC CDR2 having the amino acid sequence of SEQ ID NO: 83, and HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, an anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid #14704898vlsequence of SEQ ID NO: 44, LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000141] In some embodiments, an anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 98; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 83; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, an anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 44; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of SEQ ID NO: 89; and / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000142] In some embodiments, according to the IMGT definition system, an anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 99, a HC CDR2 having the amino acid sequence of SEQ ID NO: 86, a HC CDR3 having the amino acid sequence of SEQ ID NO: 87 a LC CDR1 having the amino acid sequence of SEQ ID NO: 91, a LC CDR2 having the amino acid sequence of LAS, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000143] In some embodiments, an anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 99, HC CDR2 having the amino acid sequence of SEQ ID NO: 86, and HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 91, LC CDR2 having the amino acid sequence of LAS, and LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000144] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at #14704898vlleast 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 99, HC CDR2 having the amino acid sequence of SEQ ID NO: 86, and HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, an anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 91, LC CDR2 having the amino acid sequence of LAS, and LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000145] In some embodiments, an anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 99; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 86; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, an anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 91; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of LAS; and / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000146] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 24. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL comprising the amino acid sequence of SEQ ID NO: 66.[000147] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VH as set forth in SEQ ID NO: 24. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared #14704898vlwith the VL as set forth in SEQ ID NO: 66. In some embodiments, the number of amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) may occur within a VH of SEQ ID NO: 24 and / or a VL of SEQ ID NO: 66 excluding any of the CDR sequences therein. In some embodiments, an anti-IL-13 antibodies provided herein comprise a heavy chain variable sequence that comprises a framework sequence that that contains no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation to the framework sequence of a VH of SEQ ID NO: 24, and / or a light chain variable sequence that comprises a framework sequence that that contains no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation to the framework sequence of a VL of SEQ ID NO: 66.[000148] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH comprising an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VH as set forth in SEQ ID NO: 24. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL comprising an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VL as set forth in SEQ ID NO: 66. In some embodiments, the degree of sequence variation (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) may occur within a VH of SEQ ID NO: 24, and / or a VL of SEQ ID NO: 66 excluding any of the CDR sequences therein. In some embodiments, an anti-IL-13 antibody provided herein comprise a heavy chain variable sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the framework sequence of a VH of SEQ ID NO: 24, and / or a light chain variable sequence that comprises a framework sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the framework sequence of a VL of SEQ ID NO: 66.[000149] In some embodiments, according to the Kabat definition system, the anti-IL-13 antibody of the present disclosure comprises a HC FW1 having the amino acid sequence of SEQ ID NO: 25, a HC FW2 having the amino acid sequence of SEQ ID NO: 6, a HC FW3 having the amino acid sequence of SEQ ID NO: 26, a HC FW4 having the amino acid sequence of SEQ ID NO: 8, a LC FW1 having the amino acid sequence of SEQ ID NO: 67, a LC FW2 having the #14704898vlamino acid sequence of SEQ ID NO: 48, a LC FW3 having the amino acid sequence of SEQ ID NO: 64, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000150] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC FW1, a HC FW2, a HC FW3, and a HC FW4, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC FW1 having the amino acid sequence of SEQ ID NO: 25, HC FW2 having the amino acid sequence of SEQ ID NO: 6, HC FW3 having the amino acid sequence of SEQ ID NO: 26, and HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC FW1, a LC FW2, a LC FW3, and a LC FW4, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC FW1 having the amino acid sequence of SEQ ID NO: 67, LC FW2 having the amino acid sequence of SEQ ID NO: 48, LC FW3 having the amino acid sequence of SEQ ID NO: 64, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000151] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC FW1, a HC FW2, a HC FW3, and a HC FW4 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC FW1 having the amino acid sequence of SEQ ID NO: 25, HC FW2 having the amino acid sequence of SEQ ID NO: 6, HC FW3 having the amino acid sequence of SEQ ID NO: 26, and HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC FW1, a LC FW2, a LC FW3, and a LC FW4 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC FW1 having the amino acid sequence of SEQ ID NO: 67, LC FW2 having the amino acid sequence of SEQ ID NO: 48, LC FW3 having the amino acid sequence of SEQ ID NO: 64, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000152] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC FW1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW1 having the amino acid sequence of SEQ ID NO: 25; a HC FW2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW2 having the amino acid sequence of SEQ ID NO: 6; a HC FW3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW3 having the amino acid sequence of SEQ ID NO: 26; #14704898vland / or a HC FW4 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC FW1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW1 having the amino acid sequence of SEQ ID NO: 67; a LC FW2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW2 having the amino acid sequence of SEQ ID NO: 48; a LC FW3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW3 having the amino acid sequence of SEQ ID NO: 64; and / or a LC FW4 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000153] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 24. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 80.[000154] In some embodiments, according to the Kabat definition system, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 2, a HC CDR2 having the amino acid sequence of SEQ ID NO: 3, a HC CDR3 having the amino acid sequence of SEQ ID NO: 4, a LC CDR1 having the amino acid sequence of SEQ ID NO: 69, a LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000155] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 2, HC CDR2 having the amino acid sequence of SEQ ID NO: 3, and HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 69, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000156] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at #14704898vlleast 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 2, HC CDR2 having the amino acid sequence of SEQ ID NO: 3, and HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 69, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000157] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 2; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 3; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 69; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of SEQ ID NO: 45; and / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000158] In some embodiments, according to the Chothia definition system, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 98, a HC CDR2 having the amino acid sequence of SEQ ID NO: 83, a HC CDR3 having the amino acid sequence of SEQ ID NO: 84, a LC CDR1 having the amino acid sequence of SEQ ID NO: 69, a LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000159] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 98, HC CDR2 having the amino acid #14704898vlsequence of SEQ ID NO: 83, and HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 69, LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000160] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 98, HC CDR2 having the amino acid sequence of SEQ ID NO: 83, and HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 69, LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000161] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 98; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 83; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 69; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of SEQ ID NO: 89; and / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000162] In some embodiments, according to the IMGT definition system, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of #14704898vlSEQ ID NO: 99, a HC CDR2 having the amino acid sequence of SEQ ID NO: 86, a HC CDR3 having the amino acid sequence of SEQ ID NO: 87, a LC CDR1 having the amino acid sequence of SEQ ID NO: 91, a LC CDR2 having the amino acid sequence of LAS, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000163] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 99, HC CDR2 having the amino acid sequence of SEQ ID NO: 86, and HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 91, LC CDR2 having the amino acid sequence of LAS, and LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000164] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 99, HC CDR2 having the amino acid sequence of SEQ ID NO: 86, and HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 91, LC CDR2 having the amino acid sequence of LAS, and LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000165] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 99; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 86; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or #14704898vl1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 91; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of LAS; and / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000166] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 24. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL comprising the amino acid sequence of SEQ ID NO: 80.[000167] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VH as set forth in SEQ ID NO: 24. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VL as set forth in SEQ ID NO: 80. In some embodiments, the number of amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) may occur within a VH of SEQ ID NO: 24 and / or a VL of SEQ ID NO: 80 excluding any of the CDR sequences therein. In some embodiments, an anti-IL-13 antibodies provided herein comprise a heavy chain variable sequence that comprises a framework sequence that that contains no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation to the framework sequence of a VH of SEQ ID NO: 24, and / or a light chain variable sequence that comprises a framework sequence that that contains no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation to the framework sequence of a VL of SEQ ID NO: 80.[000168] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH comprising an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VH as set forth in SEQ ID NO: 24. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL comprising an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VL as set forth in SEQ ID NO: 80. In some embodiments, the degree of sequence variation (e.g., at least 75%, at least 80%, at least #14704898vl85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) may occur within a VH of SEQ ID NO: 24, and / or a VL of SEQ ID NO: 80 excluding any of the CDR sequences therein. In some embodiments, an anti-IL-13 antibody provided herein comprise a heavy chain variable sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the framework sequence of a VH of SEQ ID NO: 24, and / or a light chain variable sequence that comprises a framework sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the framework sequence of a VL of SEQ ID NO: 80.[000169] In some embodiments, according to the Kabat definition system, the anti-IL-13 antibody of the present disclosure comprises a HC FW1 having the amino acid sequence of SEQ ID NO: 25, a HC FW2 having the amino acid sequence of SEQ ID NO: 6, a HC FW3 having the amino acid sequence of SEQ ID NO: 26, a HC FW4 having the amino acid sequence of SEQ ID NO: 8, a LC FW1 having the amino acid sequence of SEQ ID NO: 77, a LC FW2 having the amino acid sequence of SEQ ID NO: 78, a LC FW3 having the amino acid sequence of SEQ ID NO: 81, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000170] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC FW1, a HC FW2, a HC FW3, and a HC FW4, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC FW1 having the amino acid sequence of SEQ ID NO: 25, HC FW2 having the amino acid sequence of SEQ ID NO: 6, HC FW3 having the amino acid sequence of SEQ ID NO: 26, and HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC FW1, a LC FW2, a LC FW3, and a LC FW4, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC FW1 having the amino acid sequence of SEQ ID NO: 77, LC FW2 having the amino acid sequence of SEQ ID NO: 78, LC FW3 having the amino acid sequence of SEQ ID NO: 81, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000171] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC FW1, a HC FW2, a HC FW3, and a HC FW4 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC FW1 having the amino acid sequence of SEQ ID NO: 25, HC FW2 having the amino acid sequence of #14704898vlSEQ ID NO: 6, HC FW3 having the amino acid sequence of SEQ ID NO: 26, and HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC FW1, a LC FW2, a LC FW3, and a LC FW4 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC FW1 having the amino acid sequence of SEQ ID NO: 77, LC FW2 having the amino acid sequence of SEQ ID NO: 78, LC FW3 having the amino acid sequence of SEQ ID NO: 81, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000172] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC FW1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW1 having the amino acid sequence of SEQ ID NO: 25; a HC FW2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW2 having the amino acid sequence of SEQ ID NO: 6; a HC FW3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW3 having the amino acid sequence of SEQ ID NO: 26; and / or a HC FW4 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC FW1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW1 having the amino acid sequence of SEQ ID NO: 77; a LC FW2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW2 having the amino acid sequence of SEQ ID NO: 78; a LC FW3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW3 having the amino acid sequence of SEQ ID NO: 81; and / or a LC FW4 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000173] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 27. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 71.[000174] In some embodiments, according to the Kabat definition system, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of #14704898vlSEQ ID NO: 2, a HC CDR2 having the amino acid sequence of SEQ ID NO: 28, a HC CDR3 having the amino acid sequence of SEQ ID NO: 4, a LC CDR1 having the amino acid sequence of SEQ ID NO: 44, a LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000175] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 2, HC CDR2 having the amino acid sequence of SEQ ID NO: 28, and HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 44, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000176] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 2, HC CDR2 having the amino acid sequence of SEQ ID NO: 28, and HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 44, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000177] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 2; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 28; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or #14704898vl1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 44; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of SEQ ID NO: 45; and / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000178] In some embodiments, according to the Chothia definition system, an anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 82, a HC CDR2 having the amino acid sequence of SEQ ID NO: 83, a HC CDR3 having the amino acid sequence of SEQ ID NO: 84 a LC CDR1 having the amino acid sequence of SEQ ID NO: 44, a LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000179] In some embodiments, an anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 82, HC CDR2 having the amino acid sequence of SEQ ID NO: 83, and HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 44, LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000180] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 82, HC CDR2 having the amino acid sequence of SEQ ID NO: 83, and HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, an anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 44, LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000181] In some embodiments, an anti-IL-13 antibody of the present disclosure comprises: a #14704898vlHC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 82; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 83; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, an anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 44; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of SEQ ID NO: 89; and / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000182] In some embodiments, according to the IMGT definition system, an anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 85, a HC CDR2 having the amino acid sequence of SEQ ID NO: 86, a HC CDR3 having the amino acid sequence of SEQ ID NO: 87 a LC CDR1 having the amino acid sequence of SEQ ID NO: 91, a LC CDR2 having the amino acid sequence of LAS, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000183] In some embodiments, an anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 85, HC CDR2 having the amino acid sequence of SEQ ID NO: 86, and HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 91, LC CDR2 having the amino acid sequence of LAS, and LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000184] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 85, HC CDR2 having the amino acid sequence of SEQ #14704898vlID NO: 86, and HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, an anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 91, LC CDR2 having the amino acid sequence of LAS, and LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000185] In some embodiments, an anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 85; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 86; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, an anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 91; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of LAS; and / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000186] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 27. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL comprising the amino acid sequence of SEQ ID NO: 71.[000187] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VH as set forth in SEQ ID NO: 27. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VL as set forth in SEQ ID NO: 71. In some embodiments, the number of amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) may occur within a VH of SEQ ID NO: 27 and / or a VL of SEQ ID NO: 71 #14704898vlexcluding any of the CDR sequences therein. In some embodiments, an anti-IL-13 antibodies provided herein comprise a heavy chain variable sequence that comprises a framework sequence that that contains no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation to the framework sequence of a VH of SEQ ID NO: 27, and / or a light chain variable sequence that comprises a framework sequence that that contains no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation to the framework sequence of a VL of SEQ ID NO: 71.[000188] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH comprising an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VH as set forth in SEQ ID NO: 27. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL comprising an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VL as set forth in SEQ ID NO: 71. In some embodiments, the degree of sequence variation (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) may occur within a VH of SEQ ID NO: 27, and / or a VL of SEQ ID NO: 71 excluding any of the CDR sequences therein. In some embodiments, an anti-IL-13 antibody provided herein comprise a heavy chain variable sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the framework sequence of a VH of SEQ ID NO: 27, and / or a light chain variable sequence that comprises a framework sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the framework sequence of a VL of SEQ ID NO: 71.[000189] In some embodiments, according to the Kabat definition system, the anti-IL-13 antibody of the present disclosure comprises a HC FW1 having the amino acid sequence of SEQ ID NO: 29, a HC FW2 having the amino acid sequence of SEQ ID NO: 30, a HC FW3 having the amino acid sequence of SEQ ID NO: 31, a HC FW4 having the amino acid sequence of SEQ ID NO: 8, a LC FW1 having the amino acid sequence of SEQ ID NO: 72, a LC FW2 having the amino acid sequence of SEQ ID NO: 48, a LC FW3 having the amino acid sequence of SEQ ID NO: 73, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000190] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC #14704898vlFW1, a HC FW2, a HC FW3, and a HC FW4, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC FW1 having the amino acid sequence of SEQ ID NO: 29, HC FW2 having the amino acid sequence of SEQ ID NO: 30, HC FW3 having the amino acid sequence of SEQ ID NO: 31, and HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC FW1, a LC FW2, a LC FW3, and a LC FW4, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC FW1 having the amino acid sequence of SEQ ID NO: 72, LC FW2 having the amino acid sequence of SEQ ID NO: 48, LC FW3 having the amino acid sequence of SEQ ID NO: 73, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000191] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC FW1, a HC FW2, a HC FW3, and a HC FW4 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC FW1 having the amino acid sequence of SEQ ID NO: 29, HC FW2 having the amino acid sequence of SEQ ID NO: 30, HC FW3 having the amino acid sequence of SEQ ID NO: 31, and HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC FW1, a LC FW2, a LC FW3, and a LC FW4 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC FW1 having the amino acid sequence of SEQ ID NO: 72, LC FW2 having the amino acid sequence of SEQ ID NO: 48, LC FW3 having the amino acid sequence of SEQ ID NO: 73, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000192] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC FW1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW1 having the amino acid sequence of SEQ ID NO: 29; a HC FW2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW2 having the amino acid sequence of SEQ ID NO: 30; a HC FW3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW3 having the amino acid sequence of SEQ ID NO: 31; and / or a HC FW4 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: #14704898vla LC FW1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW1 having the amino acid sequence of SEQ ID NO: 72; a LC FW2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW2 having the amino acid sequence of SEQ ID NO: 48; a LC FW3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW3 having the amino acid sequence of SEQ ID NO: 73; and / or a LC FW4 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000193] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 32. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 68.[000194] In some embodiments, according to the Kabat definition system, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 2, a HC CDR2 having the amino acid sequence of SEQ ID NO: 28, a HC CDR3 having the amino acid sequence of SEQ ID NO: 4, a LC CDR1 having the amino acid sequence of SEQ ID NO: 69, a LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000195] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 2, HC CDR2 having the amino acid sequence of SEQ ID NO: 28, and HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 69, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000196] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 2, HC CDR2 having the amino acid sequence of SEQ #14704898vlID NO: 28, and HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 69, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000197] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 2; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 28; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 69; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of SEQ ID NO: 45; and / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000198] In some embodiments, according to the Chothia definition system, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 82, a HC CDR2 having the amino acid sequence of SEQ ID NO: 83, a HC CDR3 having the amino acid sequence of SEQ ID NO: 84, a LC CDR1 having the amino acid sequence of SEQ ID NO: 69, a LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000199] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 82, HC CDR2 having the amino acid sequence of SEQ ID NO: 83, and HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid #14704898vlvariations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 69, LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000200] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 82, HC CDR2 having the amino acid sequence of SEQ ID NO: 83, and HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 69, LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000201] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 82; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 83; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 69; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of SEQ ID NO: 89; and / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000202] In some embodiments, according to the IMGT definition system, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 85, a HC CDR2 having the amino acid sequence of SEQ ID NO: 86, a HC CDR3 having the amino acid sequence of SEQ ID NO: 87, a LC CDR1 having the amino acid sequence of SEQ ID NO: 91, a LC CDR2 having the amino acid sequence of LAS, and a LC CDR3 having #14704898vlthe amino acid sequence of SEQ ID NO: 93.[000203] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 85, HC CDR2 having the amino acid sequence of SEQ ID NO: 86, and HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 91, LC CDR2 having the amino acid sequence of LAS, and LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000204] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 85, HC CDR2 having the amino acid sequence of SEQ ID NO: 86, and HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 91, LC CDR2 having the amino acid sequence of LAS, and LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000205] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 85; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 86; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 91; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of LAS; #14704898vland / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000206] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 32. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL comprising the amino acid sequence of SEQ ID NO: 68.[000207] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VH as set forth in SEQ ID NO: 32. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VL as set forth in SEQ ID NO: 68. In some embodiments, the number of amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) may occur within a VH of SEQ ID NO: 32 and / or a VL of SEQ ID NO: 68 excluding any of the CDR sequences therein. In some embodiments, an anti-IL-13 antibodies provided herein comprise a heavy chain variable sequence that comprises a framework sequence that that contains no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation to the framework sequence of a VH of SEQ ID NO: 32, and / or a light chain variable sequence that comprises a framework sequence that that contains no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation to the framework sequence of a VL of SEQ ID NO: 68.[000208] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH comprising an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VH as set forth in SEQ ID NO: 32. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL comprising an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VL as set forth in SEQ ID NO: 68. In some embodiments, the degree of sequence variation (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) may occur within a VH of SEQ ID NO: 32, and / or a VL of SEQ ID NO: 68 excluding any of the CDR sequences therein. In some#14704898vlembodiments, an anti-IL-13 antibody provided herein comprise a heavy chain variable sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the framework sequence of a VH of SEQ ID NO: 32, and / or a light chain variable sequence that comprises a framework sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the framework sequence of a VL of SEQ ID NO: 68.[000209] In some embodiments, according to the Kabat definition system, the anti-IL-13 antibody of the present disclosure comprises a HC FW1 having the amino acid sequence of SEQ ID NO: 29, a HC FW2 having the amino acid sequence of SEQ ID NO: 30, a HC FW3 having the amino acid sequence of SEQ ID NO: 33, a HC FW4 having the amino acid sequence of SEQ ID NO: 8, a LC FW1 having the amino acid sequence of SEQ ID NO: 70, a FW2 having the amino acid sequence of SEQ ID NO: 57, a LC FW3 having the amino acid sequence of SEQ ID NO: 58, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000210] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC FW1, a HC FW2, a HC FW3, and a HC FW4, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC FW1 having the amino acid sequence of SEQ ID NO: 29, HC FW2 having the amino acid sequence of SEQ ID NO: 30, HC FW3 having the amino acid sequence of SEQ ID NO: 33, and HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC FW1, a LC FW2, a LC FW3, and a LC FW4, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC FW1 having the amino acid sequence of SEQ ID NO: 70, LC FW2 having the amino acid sequence of SEQ ID NO: 57, LC FW3 having the amino acid sequence of SEQ ID NO: 58, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000211] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC FW1, a HC FW2, a HC FW3, and a HC FW4 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC FW1 having the amino acid sequence of SEQ ID NO: 29, HC FW2 having the amino acid sequence of SEQ ID NO: 30, HC FW3 having the amino acid sequence of SEQ ID NO: 33, and HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC FW1, a LC FW2, a LC FW3, and a LC FW4 #14704898vlthat collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC FW1 having the amino acid sequence of SEQ ID NO: 70, LC FW2 having the amino acid sequence of SEQ ID NO: 57, LC FW3 having the amino acid sequence of SEQ ID NO: 58, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000212] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC FW1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW1 having the amino acid sequence of SEQ ID NO: 29; a HC FW2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW2 having the amino acid sequence of SEQ ID NO: 30; a HC FW3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW3 having the amino acid sequence of SEQ ID NO: 33; and / or a HC FW4 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC FW1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW1 having the amino acid sequence of SEQ ID NO: 70; a LC FW2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW2 having the amino acid sequence of SEQ ID NO: 57; a LC FW3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW3 having the amino acid sequence of SEQ ID NO: 58; and / or a LC FW4 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000213] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 34. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 76.[000214] In some embodiments, according to the Kabat definition system, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 2, a HC CDR2 having the amino acid sequence of SEQ ID NO: 20, a HC CDR3 having the amino acid sequence of SEQ ID NO: 4, a LC CDR1 having the amino acid sequence of SEQ ID NO: 69, a LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and a LC #14704898vlCDR3 having the amino acid sequence of SEQ ID NO: 46.[000215] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 2, HC CDR2 having the amino acid sequence of SEQ ID NO: 20, and HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 69, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000216] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 2, HC CDR2 having the amino acid sequence of SEQ ID NO: 20, and HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 69, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000217] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 2; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 20; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 69; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of SEQ #14704898vlID NO: 45; and / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000218] In some embodiments, according to the Chothia definition system, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 82, a HC CDR2 having the amino acid sequence of SEQ ID NO: 83, a HC CDR3 having the amino acid sequence of SEQ ID NO: 84, a LC CDR1 having the amino acid sequence of SEQ ID NO: 69, a LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000219] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 82, HC CDR2 having the amino acid sequence of SEQ ID NO: 83, and HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 69, LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000220] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 82, HC CDR2 having the amino acid sequence of SEQ ID NO: 83, and HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 69, LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000221] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 82; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid #14704898vlvariation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 83; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 69; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of SEQ ID NO: 89; and / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000222] In some embodiments, according to the IMGT definition system, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 85, a HC CDR2 having the amino acid sequence of SEQ ID NO: 86, a HC CDR3 having the amino acid sequence of SEQ ID NO: 87, a LC CDR1 having the amino acid sequence of SEQ ID NO: 91, a LC CDR2 having the amino acid sequence of LAS, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000223] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 85, HC CDR2 having the amino acid sequence of SEQ ID NO: 86, and HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 91, LC CDR2 having the amino acid sequence of LAS, and LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000224] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 85, HC CDR2 having the amino acid sequence of SEQ ID NO: 86, and HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least #14704898vl90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 91, LC CDR2 having the amino acid sequence of LAS, and LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000225] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 85; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 86; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 91; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of LAS; and / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000226] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 34. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL comprising the amino acid sequence of SEQ ID NO: 76.[000227] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VH as set forth in SEQ ID NO: 34. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VL as set forth in SEQ ID NO: 76. In some embodiments, the number of amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) may occur within a VH of SEQ ID NO: 34 and / or a VL of SEQ ID NO: 76 excluding any of the CDR sequences therein. In some embodiments, an anti-IL-13 antibodies provided herein comprise a heavy chain variable sequence that comprises a framework sequence that that contains no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 #14704898vlamino acid variation to the framework sequence of a VH of SEQ ID NO: 34, and / or a light chain variable sequence that comprises a framework sequence that that contains no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation to the framework sequence of a VL of SEQ ID NO: 76.[000228] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH comprising an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VH as set forth in SEQ ID NO: 34. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL comprising an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VL as set forth in SEQ ID NO: 76. In some embodiments, the degree of sequence variation (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) may occur within a VH of SEQ ID NO: 34, and / or a VL of SEQ ID NO: 76 excluding any of the CDR sequences therein. In some embodiments, an anti-IL-13 antibody provided herein comprise a heavy chain variable sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the framework sequence of a VH of SEQ ID NO: 34, and / or a light chain variable sequence that comprises a framework sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the framework sequence of a VL of SEQ ID NO: 76.[000229] In some embodiments, according to the Kabat definition system, the anti-IL-13 antibody of the present disclosure comprises a HC FW1 having the amino acid sequence of SEQ ID NO: 35, a HC FW2 having the amino acid sequence of SEQ ID NO: 22, a HC FW3 having the amino acid sequence of SEQ ID NO: 23, a HC FW4 having the amino acid sequence of SEQ ID NO: 8, a LC FW1 having the amino acid sequence of SEQ ID NO: 77, a LC FW2 having the amino acid sequence of SEQ ID NO: 78, a LC FW3 having the amino acid sequence of SEQ ID NO: 79, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000230] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC FW1, a HC FW2, a HC FW3, and a HC FW4, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC FW1 having the amino acid sequence of SEQ ID NO: 35, HC FW2 having the amino acid #14704898vlsequence of SEQ ID NO: 22, HC FW3 having the amino acid sequence of SEQ ID NO: 23, and HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC FW1, a LC FW2, a LC FW3, and a LC FW4, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC FW1 having the amino acid sequence of SEQ ID NO: 77, LC FW2 having the amino acid sequence of SEQ ID NO: 78, LC FW3 having the amino acid sequence of SEQ ID NO: 79, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000231] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC FW1, a HC FW2, a HC FW3, and a HC FW4 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC FW1 having the amino acid sequence of SEQ ID NO: 35, HC FW2 having the amino acid sequence of SEQ ID NO: 22, HC FW3 having the amino acid sequence of SEQ ID NO: 23, and HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC FW1, a LC FW2, a LC FW3, and a LC FW4 that collectively are at least 80% e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC FW1 having the amino acid sequence of SEQ ID NO: 77, LC FW2 having the amino acid sequence of SEQ ID NO: 78, LC FW3 having the amino acid sequence of SEQ ID NO: 79, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000232] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC FW1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW1 having the amino acid sequence of SEQ ID NO: 35; a HC FW2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW2 having the amino acid sequence of SEQ ID NO: 22; a HC FW3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW3 having the amino acid sequence of SEQ ID NO: 23; and / or a HC FW4 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC FW1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW1 having the amino acid sequence of SEQ ID NO: 77; a LC FW2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid #14704898vlvariation) as compared with the LC FW2 having the amino acid sequence of SEQ ID NO: 78; a LC FW3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW3 having the amino acid sequence of SEQ ID NO: 79; and / or a LC FW4 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000233] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 34. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 80.[000234] In some embodiments, according to the Kabat definition system, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 2, a HC CDR2 having the amino acid sequence of SEQ ID NO: 20, a HC CDR3 having the amino acid sequence of SEQ ID NO: 4, a LC CDR1 having the amino acid sequence of SEQ ID NO: 69, a LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000235] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 2, HC CDR2 having the amino acid sequence of SEQ ID NO: 20, and HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 69, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000236] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 2, HC CDR2 having the amino acid sequence of SEQ ID NO: 20, and HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, #14704898vlat least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 69, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000237] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 2; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 20; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 69; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of SEQ ID NO: 45; and / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000238] In some embodiments, according to the Chothia definition system, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 82, a HC CDR2 having the amino acid sequence of SEQ ID NO: 83, a HC CDR3 having the amino acid sequence of SEQ ID NO: 84, a LC CDR1 having the amino acid sequence of SEQ ID NO: 69, a LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000239] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 82, HC CDR2 having the amino acid sequence of SEQ ID NO: 83, and HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 69, LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and LC CDR3 having the amino acid sequence of SEQ ID NO: 90. #14704898vl[000240] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% {e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 82, HC CDR2 having the amino acid sequence of SEQ ID NO: 83, and HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% {e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 69, LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000241] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations {e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 82; a HC CDR2 having no more than 3 amino acid variations e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 83; and / or a HC CDR3 having no more than 3 amino acid variations {e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations {e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 69; a LC CDR2 having no more than 3 amino acid variations {e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of SEQ ID NO: 89; and / or a LC CDR3 having no more than 3 amino acid variations {e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000242] In some embodiments, according to the IMGT definition system, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 85, a HC CDR2 having the amino acid sequence of SEQ ID NO: 86, a HC CDR3 having the amino acid sequence of SEQ ID NO: 87, a LC CDR1 having the amino acid sequence of SEQ ID NO: 91, a LC CDR2 having the amino acid sequence of LAS, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000243] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid #14704898vlvariations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 85, HC CDR2 having the amino acid sequence of SEQ ID NO: 86, and HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 91, LC CDR2 having the amino acid sequence of LAS, and LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000244] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 85, HC CDR2 having the amino acid sequence of SEQ ID NO: 86, and HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 91, LC CDR2 having the amino acid sequence of LAS, and LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000245] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 85; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 86; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 91; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of LAS; and / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 93.#14704898vl[000246] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 34. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL comprising the amino acid sequence of SEQ ID NO: 80.[000247] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VH as set forth in SEQ ID NO: 34. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VL as set forth in SEQ ID NO: 80. In some embodiments, the number of amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) may occur within a VH of SEQ ID NO: 34 and / or a VL of SEQ ID NO: 80 excluding any of the CDR sequences therein. In some embodiments, an anti-IL-13 antibodies provided herein comprise a heavy chain variable sequence that comprises a framework sequence that that contains no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation to the framework sequence of a VH of SEQ ID NO: 34, and / or a light chain variable sequence that comprises a framework sequence that that contains no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation to the framework sequence of a VL of SEQ ID NO: 80.[000248] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH comprising an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VH as set forth in SEQ ID NO: 34. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL comprising an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VL as set forth in SEQ ID NO: 80. In some embodiments, the degree of sequence variation (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) may occur within a VH of SEQ ID NO: 34, and / or a VL of SEQ ID NO: 80 excluding any of the CDR sequences therein. In some embodiments, an anti-IL-13 antibody provided herein comprise a heavy chain variable sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical #14704898vlto the framework sequence of a VH of SEQ ID NO: 34, and / or a light chain variable sequence that comprises a framework sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the framework sequence of a VL of SEQ ID NO: 80.[000249] In some embodiments, according to the Kabat definition system, the anti-IL-13 antibody of the present disclosure comprises a HC FW1 having the amino acid sequence of SEQ ID NO: 35, a HC FW2 having the amino acid sequence of SEQ ID NO: 22, a HC FW3 having the amino acid sequence of SEQ ID NO: 23, a HC FW4 having the amino acid sequence of SEQ ID NO: 8, a LC FW1 having the amino acid sequence of SEQ ID NO: 77, a LC FW2 having the amino acid sequence of SEQ ID NO: 78, a LC FW3 having the amino acid sequence of SEQ ID NO: 81, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000250] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC FW1, a HC FW2, a HC FW3, and a HC FW4, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC FW1 having the amino acid sequence of SEQ ID NO: 35, HC FW2 having the amino acid sequence of SEQ ID NO: 22, HC FW3 having the amino acid sequence of SEQ ID NO: 23, and HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC FW1, a LC FW2, a LC FW3, and a LC FW4, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC FW1 having the amino acid sequence of SEQ ID NO: 77, LC FW2 having the amino acid sequence of SEQ ID NO: 78, LC FW3 having the amino acid sequence of SEQ ID NO: 81, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000251] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC FW1, a HC FW2, a HC FW3, and a HC FW4 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC FW1 having the amino acid sequence of SEQ ID NO: 35, HC FW2 having the amino acid sequence of SEQ ID NO: 22, HC FW3 having the amino acid sequence of SEQ ID NO: 23, and HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC FW1, a LC FW2, a LC FW3, and a LC FW4 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC FW1 having the amino acid sequence of SEQ ID #14704898vlNO: 77, LC FW2 having the amino acid sequence of SEQ ID NO: 78, LC FW3 having the amino acid sequence of SEQ ID NO: 81, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000252] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC FW1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW1 having the amino acid sequence of SEQ ID NO: 35; a HC FW2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW2 having the amino acid sequence of SEQ ID NO: 22; a HC FW3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW3 having the amino acid sequence of SEQ ID NO: 23; and / or a HC FW4 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC FW1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW1 having the amino acid sequence of SEQ ID NO: 77; a LC FW2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW2 having the amino acid sequence of SEQ ID NO: 78; a LC FW3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW3 having the amino acid sequence of SEQ ID NO: 81; and / or a LC FW4 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000253] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 36. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 71.[000254] In some embodiments, according to the Kabat definition system, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 2, a HC CDR2 having the amino acid sequence of SEQ ID NO: 37, a HC CDR3 having the amino acid sequence of SEQ ID NO: 4, a LC CDR1 having the amino acid sequence of SEQ ID NO: 44, a LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000255] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid #14704898vlvariations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 2, HC CDR2 having the amino acid sequence of SEQ ID NO: 37, and HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 44, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000256] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 2, HC CDR2 having the amino acid sequence of SEQ ID NO: 37, and HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 44, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000257] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 2; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 37; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 44; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of SEQ ID NO: 45; and / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 46.#14704898vl[000258] In some embodiments, according to the Chothia definition system, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 82, a HC CDR2 having the amino acid sequence of SEQ ID NO: 83, a HC CDR3 having the amino acid sequence of SEQ ID NO: 84, a LC CDR1 having the amino acid sequence of SEQ ID NO: 44, a LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000259] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 82, HC CDR2 having the amino acid sequence of SEQ ID NO: 83, and HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 44, LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000260] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 82, HC CDR2 having the amino acid sequence of SEQ ID NO: 83, and HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 44, LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000261] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 82; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 83; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ #14704898vlID NO: 84. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 44; a LC CDR2 having no more than 3 amino acid variations e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of SEQ ID NO: 89; and / or a LC CDR3 having no more than 3 amino acid variations e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000262] In some embodiments, according to the IMGT definition system, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 85, a HC CDR2 having the amino acid sequence of SEQ ID NO: 86, a HC CDR3 having the amino acid sequence of SEQ ID NO: 87, a LC CDR1 having the amino acid sequence of SEQ ID NO: 91, a LC CDR2 having the amino acid sequence of LAS, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000263] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 85, HC CDR2 having the amino acid sequence of SEQ ID NO: 86, and HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 91, LC CDR2 having the amino acid sequence of LAS, and LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000264] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 85, HC CDR2 having the amino acid sequence of SEQ ID NO: 86, and HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 91, LC CDR2 having the amino acid sequence of LAS, and LC CDR3 #14704898vlhaving the amino acid sequence of SEQ ID NO: 93.[000265] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 85; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 86; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 91; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of LAS; and / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000266] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 36. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL comprising the amino acid sequence of SEQ ID NO: 71.[000267] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VH as set forth in SEQ ID NO: 36. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VL as set forth in SEQ ID NO: 71. In some embodiments, the number of amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) may occur within a VH of SEQ ID NO: 36 and / or a VL of SEQ ID NO: 71 excluding any of the CDR sequences therein. In some embodiments, an anti-IL-13 antibodies provided herein comprise a heavy chain variable sequence that comprises a framework sequence that that contains no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation to the framework sequence of a VH of SEQ ID NO: 36, and / or a light chain variable sequence that comprises a framework sequence that that contains no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation to the framework #14704898vlsequence of a VL of SEQ ID NO: 71.[000268] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH comprising an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VH as set forth in SEQ ID NO: 36. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL comprising an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VL as set forth in SEQ ID NO: 71. In some embodiments, the degree of sequence variation (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) may occur within a VH of SEQ ID NO: 36, and / or a VL of SEQ ID NO: 71 excluding any of the CDR sequences therein. In some embodiments, an anti-IL-13 antibody provided herein comprise a heavy chain variable sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the framework sequence of a VH of SEQ ID NO: 36, and / or a light chain variable sequence that comprises a framework sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the framework sequence of a VL of SEQ ID NO: 71.[000269] In some embodiments, according to the Kabat definition system, the anti-IL-13 antibody of the present disclosure comprises a HC FW1 having the amino acid sequence of SEQ ID NO: 21, a HC FW2 having the amino acid sequence of SEQ ID NO: 22, a HC FW3 having the amino acid sequence of SEQ ID NO: 38, a HC FW4 having the amino acid sequence of SEQ ID NO: 8, a LC FW1 having the amino acid sequence of SEQ ID NO: 72, a LC FW2 having the amino acid sequence of SEQ ID NO: 48, a LC FW3 having the amino acid sequence of SEQ ID NO: 73, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000270] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC FW1, a HC FW2, a HC FW3, and a HC FW4, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC FW1 having the amino acid sequence of SEQ ID NO: 21, HC FW2 having the amino acid sequence of SEQ ID NO: 22, HC FW3 having the amino acid sequence of SEQ ID NO: 38, and HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC FW1, a LC FW2, a LC FW3, and a #14704898vlLC FW4, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC FW1 having the amino acid sequence of SEQ ID NO: 72, LC FW2 having the amino acid sequence of SEQ ID NO: 48, LC FW3 having the amino acid sequence of SEQ ID NO: 73, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000271] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC FW1, a HC FW2, a HC FW3, and a HC FW4 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC FW1 having the amino acid sequence of SEQ ID NO: 21, HC FW2 having the amino acid sequence of SEQ ID NO: 22, HC FW3 having the amino acid sequence of SEQ ID NO: 38, and HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC FW1, a LC FW2, a LC FW3, and a LC FW4 that collectively are at least 80% e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC FW1 having the amino acid sequence of SEQ ID NO: 72, LC FW2 having the amino acid sequence of SEQ ID NO: 48, LC FW3 having the amino acid sequence of SEQ ID NO: 73, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000272] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC FW1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW1 having the amino acid sequence of SEQ ID NO: 21; a HC FW2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW2 having the amino acid sequence of SEQ ID NO: 22; a HC FW3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW3 having the amino acid sequence of SEQ ID NO: 38; and / or a HC FW4 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC FW1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW1 having the amino acid sequence of SEQ ID NO: 72; a LC FW2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW2 having the amino acid sequence of SEQ ID NO: 48; a LC FW3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW3 having the amino acid sequence of SEQ ID NO: 73; #14704898vland / or a LC FW4 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000273] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 39. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 74.[000274] In some embodiments, according to the Kabat definition system, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 2, a HC CDR2 having the amino acid sequence of SEQ ID NO: 20, a HC CDR3 having the amino acid sequence of SEQ ID NO: 4, a LC CDR1 having the amino acid sequence of SEQ ID NO: 44, a LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000275] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 2, HC CDR2 having the amino acid sequence of SEQ ID NO: 20, and HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 44, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000276] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 2, HC CDR2 having the amino acid sequence of SEQ ID NO: 20, and HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 44, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and #14704898vlLC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000277] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 2; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 20; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 4. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 44; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of SEQ ID NO: 45; and / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 46.[000278] In some embodiments, according to the Chothia definition system, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 82, a HC CDR2 having the amino acid sequence of SEQ ID NO: 83, a HC CDR3 having the amino acid sequence of SEQ ID NO: 84, a LC CDR1 having the amino acid sequence of SEQ ID NO: 44, a LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000279] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 82, HC CDR2 having the amino acid sequence of SEQ ID NO: 83, and HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 44, LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000280] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at #14704898vlleast 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 82, HC CDR2 having the amino acid sequence of SEQ ID NO: 83, and HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% {e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 44, LC CDR2 having the amino acid sequence of SEQ ID NO: 89, and LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000281] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations {e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 82; a HC CDR2 having no more than 3 amino acid variations e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 83; and / or a HC CDR3 having no more than 3 amino acid variations {e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 84. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations {e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 44; a LC CDR2 having no more than 3 amino acid variations {e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of SEQ ID NO: 89; and / or a LC CDR3 having no more than 3 amino acid variations {e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 90.[000282] In some embodiments, according to the IMGT definition system, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 85, a HC CDR2 having the amino acid sequence of SEQ ID NO: 86, a HC CDR3 having the amino acid sequence of SEQ ID NO: 87, a LC CDR1 having the amino acid sequence of SEQ ID NO: 91, a LC CDR2 having the amino acid sequence of LAS, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000283] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations {e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 85, HC CDR2 having the amino acid sequence of SEQ ID NO: 86, and HC CDR3 having the amino acid sequence of SEQ ID NO: 87. #14704898vlAlternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 91, LC CDR2 having the amino acid sequence of LAS, and LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000284] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 85, HC CDR2 having the amino acid sequence of SEQ ID NO: 86, and HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 91, LC CDR2 having the amino acid sequence of LAS, and LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000285] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 85; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 86; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 87. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 91; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of LAS; and / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 93.[000286] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 39. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL comprising the amino acid#14704898vlsequence of SEQ ID NO: 74.[000287] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VH as set forth in SEQ ID NO: 39. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VL as set forth in SEQ ID NO: 74. In some embodiments, the number of amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) may occur within a VH of SEQ ID NO: 39 and / or a VL of SEQ ID NO: 74 excluding any of the CDR sequences therein. In some embodiments, an anti-IL-13 antibodies provided herein comprise a heavy chain variable sequence that comprises a framework sequence that that contains no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation to the framework sequence of a VH of SEQ ID NO: 39, and / or a light chain variable sequence that comprises a framework sequence that that contains no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation to the framework sequence of a VL of SEQ ID NO: 74.[000288] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VH comprising an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VH as set forth in SEQ ID NO: 39. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a VL comprising an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VL as set forth in SEQ ID NO: 74. In some embodiments, the degree of sequence variation (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) may occur within a VH of SEQ ID NO: 39, and / or a VL of SEQ ID NO: 74 excluding any of the CDR sequences therein. In some embodiments, an anti-IL-13 antibody provided herein comprise a heavy chain variable sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the framework sequence of a VH of SEQ ID NO: 39, and / or a light chain variable sequence that comprises a framework sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least #14704898vl97%, at least 98%, or at least 99% identical to the framework sequence of a VL of SEQ ID NO: 74.[000289] In some embodiments, according to the Kabat definition system, the anti-IL-13 antibody of the present disclosure comprises a HC FW1 having the amino acid sequence of SEQ ID NO: 40, a HC FW2 having the amino acid sequence of SEQ ID NO: 41, a HC FW3 having the amino acid sequence of SEQ ID NO: 42, a HC FW4 having the amino acid sequence of SEQ ID NO: 8, a LC FW1 having the amino acid sequence of SEQ ID NO: 72, a LC FW2 having the amino acid sequence of SEQ ID NO: 48, a LC FW3 having the amino acid sequence of SEQ ID NO: 75, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000290] In some embodiments, anti-IL-13 antibody of the present disclosure comprises a HC FW1, a HC FW2, a HC FW3, and a HC FW4, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC FW1 having the amino acid sequence of SEQ ID NO: 40, HC FW2 having the amino acid sequence of SEQ ID NO: 41, HC FW3 having the amino acid sequence of SEQ ID NO: 42, and HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC FW1, a LC FW2, a LC FW3, and a LC FW4, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC FW1 having the amino acid sequence of SEQ ID NO: 72, LC FW2 having the amino acid sequence of SEQ ID NO: 48, LC FW3 having the amino acid sequence of SEQ ID NO: 75, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000291] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a HC FW1, a HC FW2, a HC FW3, and a HC FW4 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC FW1 having the amino acid sequence of SEQ ID NO: 40, HC FW2 having the amino acid sequence of SEQ ID NO: 41, HC FW3 having the amino acid sequence of SEQ ID NO: 42, and HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises a LC FW1, a LC FW2, a LC FW3, and a LC FW4 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC FW1 having the amino acid sequence of SEQ ID NO: 72, LC FW2 having the amino acid sequence of SEQ ID NO: 48, LC FW3 having the amino acid sequence of SEQ ID NO: 75, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.#14704898vl[000292] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises: a HC FW1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW1 having the amino acid sequence of SEQ ID NO: 40; a HC FW2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW2 having the amino acid sequence of SEQ ID NO: 41; a HC FW3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW3 having the amino acid sequence of SEQ ID NO: 42; and / or a HC FW4 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC FW4 having the amino acid sequence of SEQ ID NO: 8. Alternatively or in addition, the anti-IL-13 antibody of the present disclosure comprises: a LC FW1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW1 having the amino acid sequence of SEQ ID NO: 72; a LC FW2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW2 having the amino acid sequence of SEQ ID NO: 48; a LC FW3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW3 having the amino acid sequence of SEQ ID NO: 75; and / or a LC FW4 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000293] In some embodiments, the present disclosure provides improved humanized antibodies, the improvement comprises a set of heavy chain variable region framework sequences grafted with HC CDRs of a murine antibody, and / or a set of heavy chain variable region framework sequences grafted with HC CDRs of a murine antibody. In some embodiments, a set of heavy chain FW1, FW2, FW3, and FW4 from any one of the VH FW sets selected from Table 3a, and / or a set of light chain FW1, FW2, FW3, and FW4 selected from any one of the VL FW sets selected from Table 3b can be grafted with any suitable CDRs (e.g., CDRs from an anti-IL-13 antibody or an antibody targeting a different antigen) to generate a humanized antibody with improved property (e.g., improved developability).[000294] Illustrative, non-limiting examples of heavy chain framework 1 (HC FW1), heavy chain framework 2 (HC FW2), heavy chain framework 3 (HC FW3), and heavy chain framework 4 (HC FW4) are provided in Table 3a.#14704898vlTable 3a: Heavy Chain Framework Sets According to Kabat[000295] In some embodiments, the present disclosure provides an antibody (e.g., an antibody targeting any suitable antigen) comprises a set of HC FWs corresponding to any one of the HC FW sets listed in Table 3 a.[000296] In some embodiments, an antibody comprises a heavy chain FW (e.g., HC FW1, HC FW2, HC FW3, and / or HC FW4) selected from any one of the HC FWs listed in Table 3a. In some embodiments, an antibody comprises an HC FW1 selected from any one of the HC FWls listed in Table 3a. In some embodiments, an antibody comprises an HC FW2 selected from any one of the HC FW2s listed in Table 3a. In some embodiments, an antibody comprises an HC FW3 selected from any one of the HC FW3s listed in Table 3a. In some embodiments, an antibody comprises an HC FW4 selected from any one of the HC FW4s listed in Table 3a. In #14704898vlsome embodiments, an antibody comprises the HC FW1, HC FW2, HC FW3, and HC FW4 corresponding to any one of HC FW Sets 1-7 as set forth in Table 3a.[000297] In some embodiments, according to the Kabat definition system, an antibody comprises a HC FW1 having the amino acid sequence of SEQ ID NO: 21, a HC FW2 having the amino acid sequence of SEQ ID NO: 22, a HC FW3 having the amino acid sequence of SEQ ID NO: 23, and a HC FW4 having the amino acid sequence of SEQ ID NO: 8.[000298] In some embodiments, according to the Kabat definition system, an antibody comprises a HC FW1 having the amino acid sequence of SEQ ID NO: 25, a HC FW2 having the amino acid sequence of SEQ ID NO: 6, a HC FW3 having the amino acid sequence of SEQ ID NO: 26, and a HC FW4 having the amino acid sequence of SEQ ID NO: 8.[000299] In some embodiments, according to the Kabat definition system, an antibody comprises a HC FW1 having the amino acid sequence of SEQ ID NO: 29, a HC FW2 having the amino acid sequence of SEQ ID NO: 30, a HC FW3 having the amino acid sequence of SEQ ID NO: 31, and a HC FW4 having the amino acid sequence of SEQ ID NO: 8.[000300] In some embodiments, according to the Kabat definition system, an antibody comprises a HC FW1 having the amino acid sequence of SEQ ID NO: 29, a HC FW2 having the amino acid sequence of SEQ ID NO: 30, a HC FW3 having the amino acid sequence of SEQ ID NO: 33, and a HC FW4 having the amino acid sequence of SEQ ID NO: 8.[000301] In some embodiments, according to the Kabat definition system, an antibody comprises a HC FW1 having the amino acid sequence of SEQ ID NO: 35, a HC FW2 having the amino acid sequence of SEQ ID NO: 22, a HC FW3 having the amino acid sequence of SEQ ID NO: 23, and a HC FW4 having the amino acid sequence of SEQ ID NO: 8.[000302] In some embodiments, according to the Kabat definition system, an antibody comprises a HC FW1 having the amino acid sequence of SEQ ID NO: 21, a HC FW2 having the amino acid sequence of SEQ ID NO: 22, a HC FW3 having the amino acid sequence of SEQ ID NO: 38, and a HC FW4 having the amino acid sequence of SEQ ID NO: 8.[000303] In some embodiments, according to the Kabat definition system, an antibody comprises a HC FW1 having the amino acid sequence of SEQ ID NO: 40, a HC FW2 having the amino acid sequence of SEQ ID NO: 41, a HC FW3 having the amino acid sequence of SEQ ID NO: 42, and a HC FW4 having the amino acid sequence of SEQ ID NO: 8.[000304] Illustrative, non-limiting examples of light chain framework 1 (LC FW1), light chain framework 2 (LC FW2), light chain framework 3 (LC FW3), and light chain framework 4 (LC FW4) are provided in Table 3b.#14704898vlTable 3b: Light Chain Framework Sets According to Kabat[000305] In some embodiments, the present disclosure provides an antibody (e.g., an antibody targeting any suitable antigen) comprises a set of FWs of a VL corresponding to any one of the and / or any one of the LC FW sets listed in Table 3b.[000306] In some embodiments, an antibody comprises an LC FW (e.g., LC FW1, LC FW2, LC FW3, and / or LC FW4) selected from any one of the LC FWs listed in Table 3b. In some embodiments, an antibody comprises an LC FW1 selected from any one of the LC FWls listed in Table 3b. In some embodiments, an antibody comprises an LC FW2 selected from any one of the LC FW2s listed in Table 3b. In some embodiments, an antibody comprises an LC FW3 selected from any one of the LC FW3s listed in Table 3b. In some embodiments, an antibody#14704898vlcomprises an LC FW4 selected from any one of the LC FW4s listed in Table 3b. In some embodiments, an antibody comprises the LC FW1, LC FW2, LC FW3, and LC FW4 corresponding to any one of LC FW Sets 1-7 as set forth in Table 3b.[000307] In some embodiments, according to the Kabat definition system, an antibody comprises a LC FW1 having the amino acid sequence of SEQ ID NO: 47, a LC FW2 having the amino acid sequence of SEQ ID NO: 48, a LC FW3 having the amino acid sequence of SEQ ID NO: 64, and a LC FW4 having the amino acid sequence of SEQ ID NO: 64.[000308] In some embodiments, according to the Kabat definition system, an antibody comprises a LC FW1 having the amino acid sequence of SEQ ID NO: 67, a LC FW2 having the amino acid sequence of SEQ ID NO: 48, a LC FW3 having the amino acid sequence of SEQ ID NO: 64, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000309] In some embodiments, according to the Kabat definition system, an antibody comprises a LC FW1 having the amino acid sequence of SEQ ID NO: 77, a LC FW2 having the amino acid sequence of SEQ ID NO: 78, a LC FW3 having the amino acid sequence of SEQ ID NO: 81, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000310] In some embodiments, according to the Kabat definition system, an antibody comprises a LC FW1 having the amino acid sequence of SEQ ID NO: 72, a LC FW2 having the amino acid sequence of SEQ ID NO: 48, a LC FW3 having the amino acid sequence of SEQ ID NO: 73, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000311] In some embodiments, according to the Kabat definition system, an antibody comprises a LC FW1 having the amino acid sequence of SEQ ID NO: 70, a LC FW2 having the amino acid sequence of SEQ ID NO: 57, a LC FW3 having the amino acid sequence of SEQ ID NO: 58, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000312] In some embodiments, according to the Kabat definition system, an antibody comprises a LC FW1 having the amino acid sequence of SEQ ID NO: 77, a LC FW2 having the amino acid sequence of SEQ ID NO: 78, a LC FW3 having the amino acid sequence of SEQ ID NO: 79, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000313] In some embodiments, according to the Kabat definition system, an antibody comprises a LC FW1 having the amino acid sequence of SEQ ID NO: 72, a LC FW2 having the amino acid sequence of SEQ ID NO: 48, a LC FW3 having the amino acid sequence of SEQ ID NO: 75, and a LC FW4 having the amino acid sequence of SEQ ID NO: 65.[000314] In some embodiments, the present disclosure provides an antibody comprising: (i) HC CDR1, HC CDR2, and HC CDR3 grafted into any one of the HC FW set 1-7 set forth in Table 3a; and (ii) LC CDR1, LC CDR2, and LC CDR3 grafted into any one of the LC FW set 1-7 set forth in Table 3b. Table 5 sets forth the possible combinations HC FW set and LC FW set for an #14704898vlantibody. In some embodiments, an antibody comprises a HC FW set, the sequences of which are derived from or correspond to or are the same as the sequences of the HC FW set listed in the left column of Table 5, and a LC FW set, the sequences of which are derived from or correspond to or are the same as the sequences of LC FW set listed in the corresponding row in the right column of Table 5. The sequences of HC FW sets are listed in Table 3 a, and the sequences of the LC FW sets are listed in Tables 3b.Table 5. HC FW set and LC FW Set Combination#14704898vl[000315] In some embodiments, the present disclosure provides an antibody comprising: (i) HC CDR1, HC CDR2, and HC CDR3 grafted into HC FW Set 1 in Table 3a; and (ii) LC CDR1, LC CDR2, and LC CDR3 grafted into any one of the LC FW Set 1 in Table 3b.[000316] In some embodiments, the present disclosure provides an antibody comprising: (i) HC CDR1, HC CDR2, and HC CDR3 grafted into HC FW Set 2 in Table 3a; and (ii) LC CDR1, LC CDR2, and LC CDR3 grafted into any one of the LC FW Set 2 in Table 3b.[000317] In some embodiments, the present disclosure provides an antibody comprising: (i) HC CDR1, HC CDR2, and HC CDR3 grafted into HC FW Set 2 in Table 3a; and (ii) LC CDR1, LC CDR2, and LC CDR3 grafted into any one of the LC FW Set 3 in Table 3b.[000318] In some embodiments, the present disclosure provides an antibody comprising: (i) HC CDR1, HC CDR2, and HC CDR3 grafted into HC FW Set 3 in Table 3a; and (ii) LC CDR1, LC CDR2, and LC CDR3 grafted into any one of the LC FW Set 4 in Table 3b.[000319] In some embodiments, the present disclosure provides an antibody comprising: (i) HC CDR1, HC CDR2, and HC CDR3 grafted into HC FW Set 4 in Table 3a; and (ii) LC CDR1, LC CDR2, and LC CDR3 grafted into any one of the LC FW Set 5 in Table 3b.[000320] In some embodiments, the present disclosure provides an antibody comprising: (i) HC CDR1, HC CDR2, and HC CDR3 grafted into HC FW Set 5 in Table 3a; and (ii) LC CDR1, LC CDR2, and LC CDR3 grafted into any one of the LC FW Set 6 in Table 3b.[000321] In some embodiments, the present disclosure provides an antibody comprising: (i) HC CDR1, HC CDR2, and HC CDR3 grafted into HC FW Set 6 in Table 3a; and (ii) LC CDR1, LC CDR2, and LC CDR3 grafted into any one of the LC FW Set 4 in Table 3b.[000322] In some embodiments, the present disclosure provides an antibody comprising: (i) HC CDR1, HC CDR2, and HC CDR3 grafted into HC FW Set 7 in Table 3a; and (ii) LC CDR1, LC CDR2, and LC CDR3 grafted into any one of the LC FW Set 7 in Table 3b.[000323] In some embodiments, the anti-IL-13 antibody of the present disclosure is a chimeric antibody, which can include a heavy constant region and a light constant region from a human antibody. Chimeric antibodies refer to antibodies having a variable region or part of variable region from a first species and a constant region from a second species. Typically, in these chimeric antibodies, the variable region of both light and heavy chains mimics the variable regions of antibodies derived from one species of mammals (e.g., a non-human mammal such as mouse, rabbit, and rat), while the constant portions are homologous to the sequences in antibodies derived from another mammal such as human. In some embodiments, amino acid modifications can be made in the variable region and / or the constant region.#14704898vl[000324] In some embodiments, the anti-IL-13 antibody described herein is a chimeric antibody, which can include a heavy constant region and a light constant region from a human antibody. Chimeric antibodies refer to antibodies having a variable region or part of variable region from a first species and a constant region from a second species. Typically, in these chimeric antibodies, the variable region of both light and heavy chains mimics the variable regions of antibodies derived from one species of mammals (e.g., a non-human mammal such as mouse, rabbit, and rat), while the constant portions are homologous to the sequences in antibodies derived from another mammal such as human. In some embodiments, amino acid modifications can be made in the variable region and / or the constant region.[000325] In some embodiments, the anti-IL-13 antibody of the present disclosure comprises a VL domain and / or VH domain of any one of the anti-IL-13 antibodies selected from Table 2, and comprises a constant region comprising the amino acid sequences of the constant regions of an IgG, IgE, IgM, IgD, IgA or IgY immunoglobulin molecule, any class (e.g., IgGl, IgG2, IgG3, IgG4, IgAl and IgA2), or any subclass (e.g., IgG2a and IgG2b) of immunoglobulin molecule. Non-limiting examples of human constant regions are described in the art, e.g., see Kabat E A et al., (1991) supra.[000326] In some embodiments, the light chain of any of the anti-IL-13 antibodies described herein may further comprise a light chain constant region (CL), which can be any CL known in the art. In some examples, the CL is a kappa light chain. In other examples, the CL is a lambda light chain. In some embodiments, the CL is a kappa light chain.[000327] Other antibody heavy and light chain constant regions are well known in the art, e.g., those provided in the IMGT database (imgt.org) or at vbase2.org / vbstat.php., both of which are incorporated by reference herein.[000328] The anti-IL-13 antibodies described herein can be in any antibody form, including, but not limited to, intact (i.e., full-length) antibodies, antigen-binding fragments thereof (such as Fab, F(ab'), F(ab')2, Fv), single chain antibodies, bi-specific antibodies, or nanobodies. In some embodiments, the anti-IL-13 antibody described herein is a scFv. In some embodiments, the anti-IL-13 antibody described herein is a scFv-Fab (e.g., scFv fused to a portion of a constant region).[000329] In some embodiments, conservative mutations can be introduced into antibody sequences (e.g., CDRs or framework sequences) at positions where the residues are not likely to be involved in interacting with a target antigen (e.g., IL-13), for example, as determined based on a crystal structure. In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the Fc region of an anti-IL-13 antibody described herein (e.g., in a CH2 domain (residues 231-340 of human IgGl) and / or CH3 domain (residues 341-447 of #14704898vlhuman IgGl) and / or the hinge region, with numbering according to the Kabat numbering system (e.g., the EU index in Kabat)) to alter one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding and / or antigen-dependent cellular cytotoxicity.[000330] In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the hinge region of the Fc region (CHI domain) such that the number of cysteine residues in the hinge region are altered (e.g., increased or decreased) as described in, e.g., U.S. Pat. No. 5,677,425. The number of cysteine residues in the hinge region of the CHI domain can be altered to, e.g., facilitate assembly of the light and heavy chains, or to alter (e.g., increase or decrease) the stability of the antibody or to facilitate linker conjugation.[000331] In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the Fc region of an antibody described herein (e.g., in a CH2 domain (residues 231-340 of human IgGl) and / or CH3 domain (residues 341-447 of human IgGl) and / or the hinge region, with numbering according to the Kabat numbering system (e.g., the EU index in Kabat)) to increase or decrease the affinity of the antibody for an Fc receptor (e.g., an activated Fc receptor) on the surface of an effector cell. Mutations in the Fc region of an antibody that decrease or increase the affinity of an antibody for an Fc receptor and techniques for introducing such mutations into the Fc receptor or fragment thereof are known to one of skill in the art. Examples of mutations in the Fc receptor of an antibody that can be made to alter the affinity of the antibody for an Fc receptor are described in, e.g., Smith P et al., (2012) PNAS 109: 6181-6186, U.S. Pat. No. 6,737,056, and International Publication Nos. WO 02 / 060919; WO 98 / 23289; and WO 97 / 34631, which are incorporated herein by reference.[000332] In some embodiments, one, two or more amino acid mutations (i.e., substitutions, insertions, or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to alter (e.g., decrease or increase) halflife of the antibody in vivo. See, e.g., International Publication Nos. WO 02 / 060919; WO 98 / 23289; and WO 97 / 34631; and U.S. Pat. Nos. 5,869,046, 6,121,022, 6,277,375 and 6,165,745 for examples of mutations that will alter (e.g., decrease or increase) the half-life of an antibody in vivo.[000333] In some embodiments, one, two or more amino acid mutations (i.e., substitutions, insertions, or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to decrease the half-life of the anti-IE-13 antibody in vivo. In some embodiments, one, two or more amino acid mutations (i.e., substitutions, insertions, or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to increase the half-life #14704898vlof the antibody in vivo. In some embodiments, the antibodies can have one or more amino acid mutations (e.g., substitutions) in the second constant (CH2) domain (residues 231-340 of human IgGl) and / or the third constant (CH3) domain (residues 341-447 of human IgGl), with numbering according to the EU index in Kabat (Kabat E A et al., (1991) supra). In some embodiments, the constant region of the IgGl of an antibody described herein comprises a methionine (M) to tyrosine (Y) substitution in position 252, a serine (S) to threonine (T) substitution in position 254, and a threonine (T) to glutamic acid (E) substitution in position 256, numbered according to the EU index as in Kabat. See U.S. Pat. No. 7,658,921, which is incorporated herein by reference. This type of mutant IgG, referred to as "YTE mutant" has been shown to display fourfold increased half-life as compared to wild-type versions of the same antibody (see Dall'Acqua W F et al., (2006) J Biol Chem 281: 23514-24). In some embodiments, an antibody comprises an IgG constant domain comprising one, two, three or more amino acid substitutions of amino acid residues at positions 251-257, 285-290, 308-314, 385-389, and 428-436, numbered according to the EU index as in Kabat.[000334] In some embodiments, one, two or more amino acid substitutions are introduced into an IgG constant domain Fc region to alter the effector function(s) of the anti-IL-13 antibody. The effector ligand to which affinity is altered can be, for example, an Fc receptor or the Cl component of complement. This approach is described in further detail in U.S. Pat. Nos.5,624,821 and 5,648,260. In some embodiments, the deletion or inactivation (through point mutations or other means) of a constant region domain can reduce Fc receptor binding of the circulating antibody thereby increasing tumor localization. See, e.g., U.S. Pat. Nos. 5,585,097 and 8,591,886 for a description of mutations that delete or inactivate the constant domain and thereby increase tumor localization. In some embodiments, one or more amino acid substitutions may be introduced into the Fc region of an antibody described herein to remove potential glycosylation sites on Fc region, which may reduce Fc receptor binding (see, e.g., Shields R L et al., (2001) J Biol Chem 276: 6591-604).[000335] In some embodiments, one or more amino in the constant region of an anti-IL-13 antibody described herein can be replaced with a different amino acid residue such that the antibody has altered Clq binding and / or reduced or abolished complement dependent cytotoxicity (CDC). This approach is described in further detail in U.S. Pat. No. 6,194,551 (Idusogie et al). In some embodiments, one or more amino acid residues in the N-terminal region of the CH2 domain of an antibody described herein are altered to thereby alter the ability of the antibody to fix complement. This approach is described further in International Publication No. WO 94 / 29351. In some embodiments, the Fc region of an antibody described herein is modified to increase the ability of the antibody to mediate antibody dependent cellular cytotoxicity #14704898vl(ADCC) and / or to increase the affinity of the antibody for an Fey receptor. This approach is described further in International Publication No. WO 00 / 42072.[000336] In some embodiments, the heavy and / or light chain variable domain(s) sequence(s) of the antibodies provided herein can be used to generate, for example, CDR-grafted, chimeric, humanized, or composite human antibodies or antigen-binding fragments, as described elsewhere herein. As understood by one of ordinary skill in the art, any variant, CDR-grafted, chimeric, humanized, or composite antibodies derived from any of the antibodies provided herein may be useful in the compositions and methods described herein and will maintain the ability to specifically bind IL-13, such that the variant, CDR-grafted, chimeric, humanized, or composite antibody has at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or more binding to IL- 13 relative to the original antibody from which it is derived.[000337] In some embodiments, the antibodies provided herein comprise mutations that confer desirable properties to the antibodies. For example, to avoid potential complications due to Fabarm exchange, which is known to occur with native IgG4 mAbs, the antibodies provided herein may comprise a stabilizing ‘Adair’ mutation (Angal S., et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse / human (IgG4) antibody,” Mol Immunol 30, 105-108; 1993), where serine 228 (EU numbering; residue 241 Kabat numbering) is converted to proline resulting in an IgGl-like hinge sequence. Accordingly, any of the antibodies may include a stabilizing ‘Adair’ mutation.[000338] In some embodiments, an antibody is modified, e.g., modified via glycosylation, phosphorylation, sumoylation, and / or methylation. In some embodiments, an antibody is a glycosylated antibody, which is conjugated to one or more sugar or carbohydrate molecules. In some embodiments, the one or more sugar or carbohydrate molecule are conjugated to the antibody via N-glycosylation, O-glycosylation, C-glycosylation, glypiation (GPI anchor attachment), and / or phosphoglycosylation. In some embodiments, the one or more sugar or carbohydrate molecules are monosaccharides, disaccharides, oligosaccharides, or glycans. In some embodiments, the one or more sugar or carbohydrate molecule is a branched oligosaccharide or a branched glycan. In some embodiments, the one or more sugar or carbohydrate molecule includes a mannose unit, a glucose unit, an N-acetylglucosamine unit, an N-acetylgalactosamine unit, a galactose unit, a fucose unit, or a phospholipid unit. In some embodiments, there are about 1-10, about 1-5, about 5-10, about 1-4, about 1-3, or about 2 sugar molecules. In some embodiments, a glycosylated antibody is fully or partially glycosylated. In some embodiments, an antibody is glycosylated by chemical reactions or by enzymatic means. In some embodiments, an antibody is glycosylated in vitro or inside a cell, which may optionally be deficient in an enzyme in the N- or O- glycosylation pathway, e.g., a glycosyltransferase. In #14704898vlsome embodiments, an antibody is functionalized with sugar or carbohydrate molecules as described in International Patent Application Publication WO2014065661, published on May 1, 2014, entitled, “Modified antibody, antibody-conjugate and process for the preparation thereof’.[000339] In some embodiments, any one of the anti-IL-13 antibodies described herein may comprise a signal peptide in the heavy and / or light chain sequence (e.g., a N-terminal signal peptide). In some embodiments, the anti-IL-13 antibody described herein comprises any one of the VH and VL sequences, any one of the IgG heavy chain and light chain sequences, or any one of the F(ab') heavy chain and light chain sequences described herein, and further comprises a signal peptide (e.g., a N-terminal signal peptide).[000340] In some embodiments, the present disclosure provides a multi-specific antibody comprising one or more arms that comprises an antigen specific binding site from an anti-IL-13 antibody described herein (e.g., an anti-IL-13 antibody set forth in Table 2) and one or more arms that comprises an antigen specific binding site for one or more different antigens. In some embodiments, the multispecific antibody is a bispecific antibody that comprises one arm that comprises an antigen specific binding site from an anti-IL-13 antibody described herein (e.g., an anti-IL-13 antibody set forth in Table 2) and one arm that comprises an antigen specific binding site for a different antigen.[000341] In some embodiments, a multispecific antibody described herein comprises one or more arms that comprises an antigen specific binding site from an anti-IL-13 antibody described herein (e.g., an anti-IL-13 antibody set forth in Table 2), and one or more arms that comprises one or more antigen specific binding sites for different antigens, including but are not limited to: KLK5, KLK7, KLK7 / 5, IL-4 / IL-4R, TSLP / TSLPR, 0X40, OX40L, IL5 / IL-5R, IL-9 / IL-9R, IL-25 / IL-25R, IL-31 / IL-31R, I1-36 / IL-36R, IL-33 / IL-33R, etc. In some embodiments, a bispecific antibody described herein comprises one or more arms that comprises an antigen specific binding site from an anti-IL-13 antibody described herein (e.g., an anti-IL-13 antibody set forth in Table 2), and one or more arms that comprises one or more antigen specific binding sites for different antigens, including but are not limited to: KLK5, KLK7, KLK7 / 5, IL-4 / IL-4R, TSLP / TSLPR, 0X40, OX40L, IL5 / IL-5R, IL-9 / IL-9R, IL-25 / IL-25R, IL-31 / IL-31R, I1-36 / IL-36R, IL-33 / IL-33R, etc..[000342] In some embodiments, a multispecific antibody (e.g., a bispecific antibody) described herein comprises one or more arms that comprises an antigen specific binding site from an anti-IL-13 antibody described herein (e.g., an anti-IL-13 antibody set forth in Table 2), and one or more arms that comprises one or more antigen specific binding sites for KLK5 (e.g., an anti-KLK5 antibody described in WO2024187154, entitled “Kallikrein antibodies and uses thereof’, published September 12, 2024; W02005078123, entitled “DIAGNOSTICS AND#14704898vlTHERAPEUTICS FOR DISEASES ASSOCIATED WITH KALLIKREIN 5 (KLK5)”, published on August 25, 2025; WO2018195472, entitled “USE OF KLK5 ANTAGONISTS FOR TREATMENT OF A DISEASE”, published on October 25,2018; WO2019178316, entitled “Anti-klk5 antibodies and methods of use”, published September 19, 2019;WO2021156170, entitled “ANTIBODIES AGAINST KLK5”, published August 21, 2021; WO2021156171, entitled “ANTIBODIES AGAINST KLK5”, published August 21, 2021; WO2021055577, entitled “Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5 / klk7 antibodies, and methods of use”, published March 25, 2021; WO2022192647, entitled “Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5 / klk7 antibodies, and methods of use”, published September 15, 2022, the entire contents of each of which is incorporated herein by reference).[000343] In some embodiments, a multispecific antibody (e.g., a bispecific antibody) described herein comprises one or more arms that comprises an antigen specific binding site from an anti-IL-13 antibody described herein (e.g., an anti-IL-13 antibody set forth in Table 2), and one or more arms that comprises one or more antigen specific binding sites for KLK7 (e.g., an anti-KLK7 antibody described in WO2024187154, entitled “Kallikrein antibodies and uses thereof’, published September 12, 2024; W01995000651, entitled “MONOCLONAL ARECOMBINANT STRATUM CORNEUM CHYMOTRYPTIC ENZYME NTIBODIES AGAINST (SCCE)”, published January 5, 1995; W02005075667, entitled “DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH KALLIKREIN 7 (KLK7)”, published August 18, 2005; WO2021226695, entitled “RECOMBINANT HUMAN ANTIBODIES FOR INHIBITING HUMAN TISSUE KALLIKREIN 7 (KLK7) AND USE IN DISEASES RELATED TO THE PROCESS OF SKIN DESQUAMATION”, published November 18, 2021; WO2021055577, entitled “Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5 / klk7 antibodies, and methods of use”, published March 25, 2021; WO2022192647, entitled “Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5 / klk7 antibodies, and methods of use”, published September 15, 2022, the entire contents of each of which is incorporated herein by reference).[000344] In some embodiments, a multispecific antibody (e.g., a bispecific antibody) described herein comprises one or more arms that comprises an antigen specific binding site from an anti-IL-13 antibody described herein (e.g., an anti-IL-13 antibody set forth in Table 2), and one or more arms that comprises one or more antigen specific binding sites from a dual inhibitor antibody that binds both KLK5 and KLK7 (e.g., a dual inhibitor KLK5 / KLK7 antibody described in WO2024187149, entitled “Dual inhibitor Kallikrein antibodies and uses thereof’, published on September 12, 2024, the entire contents of each of which is incorporated herein by reference).#14704898vlIII. Preparation of the Anti-IL-13 Antibodies[000345] Antibodies capable of binding IL- 13 as described herein can be made by any method known in the art. See, for example, Harlow and Lane, (1998) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York.[000346] In some embodiments, antibodies specific to a target antigen (e.g., IL- 13) can be made by the conventional hybridoma technology. The full-length target antigen or a fragment thereof, optionally coupled to a carrier protein such as KLH, can be used to immunize a host animal for generating antibodies binding to that antigen. The route and schedule of immunization of the host animal are generally in keeping with established and conventional techniques for antibody stimulation and production, as further described herein. General techniques for production of mouse, humanized, and human antibodies are known in the art and are described herein. It is contemplated that any mammalian subject including humans or antibody producing cells therefrom can be manipulated to serve as the basis for production of mammalian, including human hybridoma cell lines. Typically, the host animal is inoculated intraperitoneally, intramuscularly, orally, subcutaneously, intraplantar, and / or intradermally with an amount of immunogen, including as described herein.[000347] If desired, an antibody (monoclonal or polyclonal) of interest (e.g., produced by a hybridoma) may be sequenced and the polynucleotide sequence may then be cloned into a vector for expression or propagation. The sequence encoding the antibody of interest may be maintained in vector in a host cell and the host cell can then be expanded and frozen for future use. In an alternative, the polynucleotide sequence may be used for genetic manipulation to "humanize" the antibody or to improve the affinity (affinity maturation), or other characteristics of the antibody. For example, the constant region may be engineered to more resemble human constant regions to avoid immune response if the antibody is used in clinical trials and treatments in humans. It may be desirable to genetically manipulate the antibody sequence to obtain greater affinity to the target antigen and greater efficacy. It will be apparent to one of skill in the art that one or more polynucleotide changes can be made to the antibody and still maintain its binding specificity to the target antigen.[000348] In other embodiments, fully human antibodies can be obtained by using commercially available mice that have been engineered to express specific human immunoglobulin proteins. Transgenic animals that are designed to produce a more desirable (e.g., fully human antibodies) or more robust immune response may also be used for generation of humanized or human antibodies. Examples of such technology are XenomouseRTM from Amgen, Inc. (Fremont, CA) and HuMAb-MouseRTM and TC MouseTM from Medarex, Inc. (Princeton, NJ) or H2L2 mice from Harbour Antibodies BV (Holland). In another alternative, antibodies may be made#14704898vlrecombinantly by phage display or yeast technology. See, for example, U.S. Pat. Nos. 5,565,332; 5,580,717; 5,733,743; and 6,265,150; and Winter et al., (1994) Annu. Rev. Immunol. 12:433-455. Alternatively, the phage display technology (McCafferty etal., (1990) Nature 348:552-553) can be used to produce human antibodies and antibody fragments in vitro, from immunoglobulin variable (V) domain gene repertoires from unimmunized donors.[000349] Antigen-binding fragments of an intact antibody (full-length antibody) can be prepared via routine methods. For example, F(ab')2 fragments can be produced by pepsin digestion of an antibody molecule, and Fab fragments that can be generated by reducing the disulfide bridges of F(ab')2 fragments. Genetically engineered antibodies, such as humanized antibodies, chimeric antibodies, single-chain antibodies, and bi-specific antibodies, can be produced via, e.g., conventional recombinant technology. In one example, DNA encoding a monoclonal antibodies specific to a target antigen can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies). The hybridoma cells serve as a preferred source of such DNA. Once isolated, the DNA may be placed into one or more expression vectors, which are then transfected into host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, human HEK293 cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. See, e.g., PCT Publication No. WO 87 / 04462. The DNA can then be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences, Morrison et al., (1984) Proc. Nat. Acad. Sci. 81:6851, or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. In that manner, genetically engineered antibodies, such as “chimeric” or “hybrid” antibodies; can be prepared that have the binding specificity of a target antigen.[000350] A single-chain antibody can be prepared via recombinant technology by linking a nucleotide sequence coding for a heavy chain variable region and a nucleotide sequence coding for a light chain variable region. Preferably, a flexible linker is incorporated between the two variable regions.[000351] Alternatively, techniques described for the production of single chain antibodies (U.S. Patent Nos. 4,946,778 and 4,704,692) can be adapted to produce a phage or yeast scFv library and scFv clones specific to IL- 13 can be identified from the library following routine procedures. Positive clones can be subjected to further screening to identify those that has high IL- 13 binding affinity.#14704898vl[000352] Antibodies obtained following a method known in the art and described herein can be characterized using methods well known in the art. For example, one method is to identify the epitope to which the antigen binds, or “epitope mapping.” There are many methods known in the art for mapping and characterizing the location of epitopes on proteins, including solving the crystal structure of an antibody-antigen complex, competition assays, gene fragment expression assays, and synthetic peptide-based assays, as described, for example, in Chapter 11 of Harlow and Lane, Using Antibodies, a Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1999. In one example, epitope mapping can be accomplished use H / D-Ex (hydrogen deuterium exchange) coupled with proteolysis and mass spectrometry. In an additional example, epitope mapping can be used to determine the sequence to which an antibody binds. The epitope can be a linear epitope, i.e., contained in a single stretch of amino acids, or a conformational epitope formed by a three-dimensional interaction of amino acids that may not necessarily be contained in a single stretch (primary structure linear sequence). Peptides of varying lengths (e.g., at least 4-6 amino acids long) can be isolated or synthesized (e.g., recombinantly) and used for binding assays with an antibody. In another example, the epitope to which the antibody binds can be determined in a systematic screening by using overlapping peptides derived from the target antigen sequence and determining binding by the antibody. According to the gene fragment expression assays, the open reading frame encoding the target antigen is fragmented either randomly or by specific genetic constructions and the reactivity of the expressed fragments of the antigen with the antibody to be tested is determined. The gene fragments may, for example, be produced by PCR and then transcribed and translated into protein in vitro, in the presence of radioactive amino acids. The binding of the antibody to the radioactively labeled antigen fragments is then determined by immunoprecipitation and gel electrophoresis. Certain epitopes can also be identified by using large libraries of random peptide sequences displayed on the surface of phage particles (phage libraries). Alternatively, a defined library of overlapping peptide fragments can be tested for binding to the test antibody in simple binding assays. In an additional example, mutagenesis of an antigen binding domain, domain swapping experiments and alanine scanning mutagenesis can be performed to identify residues required, sufficient, and / or necessary for epitope binding. Alternatively, competition assays can be performed using other antibodies known to bind to the same antigen to determine whether an antibody binds to the same epitope as the other antibodies. Competition assays are well known to those of skill in the art.[000353] In some examples, an anti-IL-13 antibody is prepared by recombinant technology as exemplified below. Nucleic acids encoding the heavy and light chain of an anti-IL-13 antibody as described herein can be cloned into one expression vector, each nucleotide sequence being in #14704898vloperable linkage to a suitable promoter. In one example, each of the nucleotide sequences encoding the heavy chain and light chain is in operable linkage to a distinct promoter.Alternatively, the nucleotide sequences encoding the heavy chain and the light chain can be in operable linkage with a single promoter, such that both heavy and light chains are expressed from the same promoter. When necessary, an internal ribosomal entry site (IRES) can be inserted between the heavy chain and light chain encoding sequences.[000354] In some examples, the nucleotide sequences encoding the two chains of the antibody are cloned into two vectors, which can be introduced into the same or different cells. When the two chains are expressed in different cells, each of them can be isolated from the host cells expressing such and the isolated heavy chains and light chains can be mixed and incubated under suitable conditions allowing for the formation of the antibody.[000355] Generally, a nucleic acid sequence encoding one or all chains of an antibody can be cloned into a suitable expression vector in operable linkage with a suitable promoter using methods known in the art. For example, the nucleotide sequence and vector can be contacted, under suitable conditions, with a restriction enzyme to create complementary ends on each molecule that can pair with each other and be joined together with a ligase. Alternatively, synthetic nucleic acid linkers can be ligated to the termini of a gene. These synthetic linkers contain nucleic acid sequences that correspond to a particular restriction site in the vector. The selection of expression vectors / promoter would depend on the type of host cells for use in producing the antibodies.[000356] A variety of promoters can be used for expression of the antibodies described herein, including, but not limited to, cytomegalovirus (CMV) intermediate early promoter, a viral LTR such as the Rous sarcoma virus LTR, HIV-LTR, HTLV-1 LTR, the simian virus 40 (SV40) early promoter, E. coli lac UV promoter, and the herpes simplex tk virus promoter.[000357] Regulatable promoters can also be used. Such regulatable promoters include those using the lac repressor from E. coli as a transcription modulator to regulate transcription from lac operator bearing mammalian cell promoters [[Brown, M. et al., Cell, 49:603-612 (1987)]], those using the tetracycline repressor (tetR) [[Gossen, M., and Bujard, H., Proc. Natl. Acad. Sci. USA 89:5547-555115 (1992); Yao, F. et al., Human Gene Therapy, 9:1939-1950 (1998); Shockelt, P., et al., Proc. Natl. Acad. Sci. USA, 92:6522-6526 (1995)]]. Other systems include FK506 dimer, VP 16 or p65 using astradiol, RU486, diphenol murislerone, or rapamycin. Inducible systems are available from Invitrogen, Clontech and Ariad, among others.[000358] Regulatable promoters that include a repressor with the operon can be used. In one embodiment, the lac repressor from E. coli can function as a transcriptional modulator to regulate transcription from lac operator-bearing mammalian cell promoters [[M. Brown et al., Cell, #14704898vl49:603-612 (1987)]]; Gossen and Bujard (1992); [[M. Gossen etal., Natl. Acad. Sci. USA, 89:5547-5551(1992)]] combined the tetracycline repressor (tetR) with the transcription activator (VP 16) to create a tetR-mammalian cell transcription activator fusion protein, tTa (tetR- VP 16), with the tetO bearing minimal promoter derived from the human cytomegalovirus (hCMV) promoter to create a tetR-tet operator system to control gene expression in mammalian cells. In one embodiment, a tetracycline inducible switch is used. The tetracycline repressor (tetR) alone, rather than the tetR-mammalian cell transcription factor fusion derivatives can function as potent trans-modulator to regulate gene expression in mammalian cells when the tetracycline operator is properly positioned downstream for the TATA element of the CMVIE promoter (Yao et al., Human Gene Therapy). One particular advantage of this tetracycline inducible switch is that it does not require the use of a tetracycline repressor-mammalian cells transactivator or repressor fusion protein, which in some instances can be toxic to cells (Gossen 5 et al., Natl. Acad. Sci. USA, 89:5547-5551 (1992); Shocked et al., Proc. Natl. Acad. Sci. USA, 92:6522-6526 (1995)), to achieve its regulatable effects.[000359] Additionally, the vector can contain, for example, some or all of the following: a selectable marker gene, such as the neomycin gene for selection of stable or transient transfectants in mammalian cells; enhancer / promoter sequences from the immediate early gene of human CMV for high levels of transcription; transcription termination and RNA processing signals from SV40 for mRNA stability; SV40 polyoma origins of replication and ColEl for proper episomal replication; internal ribosome binding sites (IRESes), versatile multiple cloning sites; and T7 and SP6 RNA promoters for in vitro transcription of sense and antisense RNA. Suitable vectors and methods for producing vectors containing transgenes are well known and available in the art. Examples of polyadenylation signals useful to practice the methods described herein include, but are not limited to, human collagen I polyadenylation signal, human collagen II polyadenylation signal, and SV40 polyadenylation signal.[000360] One or more vectors (e.g., expression vectors) comprising nucleic acids encoding any of the antibodies (e.g., the nucleic acid coding sequences listed in Tables 4a-4b) may be introduced into suitable host cells for producing the antibodies. Non-limiting examples of the host cells include Chinese hamster ovary (CHO) cells, dhfr- CHO cell, human embryonic kidney (HEK)-293 cells, verdareno (VERO) cells, nonsecreting null (NS0) cells, human embryonic retinal (PER.C6) cells, Sp2 / 0 cells, baby hamster kidney (BHK) cells, Madin-Darby Canine Kidney (MDCK) cells, Madin-Darby Bovine Kidney (MDBK) cells, and monkey kidney CV1 line transformed by SV40 (COS) cells. In some embodiments, the host cell expressing the anti-IL-13 antibodies are CHO cells. The host cells can be cultured under suitable conditions for expression of the antibody or any polypeptide chain thereof. Such antibodies or polypeptide #14704898vlchains thereof can be recovered by the cultured cells (e.g., from the cells or the culture supernatant) via a conventional method, e.g., affinity purification. If necessary, polypeptide chains of the antibody can be incubated under suitable conditions for a suitable period of time allowing for production of the antibody. In some embodiments, the host cell comprises the nucleic acid encoding the heavy chain of the anti-IL-13 antibody. In some embodiments, the host cell comprises the nucleic acid encoding the light chain of the anti-IL-13 antibody. In some embodiments, the host cell comprises the nucleic acid encoding the heavy chain and the nucleic acid encoding the light chain.[000361] In some embodiments, methods for preparing an antibody described herein involve a recombinant expression vector that encodes both the heavy chain and the light chain of an anti-IL-13 antibody, as also described herein. The recombinant expression vector can be introduced into a suitable host cell (e.g., a dhfr- CHO cell) by a conventional method, e.g., calcium phosphate mediated transfection. Positive transformant host cells can be selected and cultured under suitable conditions allowing for the expression of the two polypeptide chains that form the antibody, which can be recovered from the cells or from the culture medium. When necessary, the two chains recovered from the host cells can be incubated under suitable conditions allowing for the formation of the antibody.[000362] In one example, two recombinant expression vectors are provided, one encoding the heavy chain of the anti-IL-13 antibody and the other encoding the light chain of the anti-IL-13 antibody. Both of the two recombinant expression vectors can be introduced into a suitable host cell (e.g., dhfr-CHO cell) by a conventional method, e.g., calcium phosphate-mediated transfection.[000363] Alternatively, each of the expression vectors can be introduced into a suitable host cell. Positive transformants can be selected and cultured under suitable conditions allowing for the expression of the polypeptide chains of the antibody. When the two expression vectors are introduced into the same host cells, the antibody produced therein can be recovered from the host cells or from the culture medium. If necessary, the polypeptide chains can be recovered from the host cells or from the culture medium and then incubated under suitable conditions allowing for formation of the antibody. When the two expression vectors are introduc...

Claims

1. CLAIMSWhat is claimed is:

1. An anti-interleukin- 13 (IL-13) antibody comprising:a heavy chain complementarity determining region 1 (HC CDR1), HC CDR2, and HC CDR3 of any one of the variable heavy chain (VH) domains in Table 2; and / ora light chain CDR 1 (LC CDR1), LC CDR2, and LC CDR3 of any one of the variable light chain domains (VL) in Table 2,wherein the anti-IL-13 antibody is obtainable at high expression titer.

2. An anti-interleukin- 13 (IL-13) antibody comprising:(a) a heavy chain complementarity determining region 1 (HC CDR1), a HC CDR2, and a HC CDR3 of a variable heavy chain (VH) domain comprising the amino acid sequence of SEQ ID NO: 19, and a light chain CDR1 (LC CDR1), LC CDR2, and LC CDR3 of a variable light chain domain (VL) comprising the amino acid sequence of SEQ ID NO: 63;(b) a HC CDR1, HC CDR2, and HC CDR3 of a VH having the amino acid sequence of SEQ ID NO: 24, and a LC CDR1, LC CDR2, and LC CDR3 of a VL having the amino acid sequence of SEQ ID NO: 66;(c) a HC CDR1, HC CDR2, and HC CDR3 of a VH having the amino acid sequence of SEQ ID NO: 24, and a LC CDR1, LC CDR2, and LC CDR3 of a VL having the amino acid sequence of SEQ ID NO: 80;(d) a HC CDR1, HC CDR2, and HC CDR3 of a VH having the amino acid sequence of SEQ ID NO: 27, and a LC CDR1, LC CDR2, and LC CDR3 of a VL having the amino acid sequence of SEQ ID NO: 71;(e) a HC CDR1, HC CDR2, and HC CDR3 of a VH having the amino acid sequence of SEQ ID NO: 32, and a LC CDR1, LC CDR2, and LC CDR3 of a VL having the amino acid sequence of SEQ ID NO: 68;(f) a HC CDR1, HC CDR2, and HC CDR3 of a VH having the amino acid sequence of SEQ ID NO: 34, and a LC CDR1, LC CDR2, and LC CDR3 of a VL having the amino acid sequence of SEQ ID NO: 76;(g) a HC CDR1, HC CDR2, and HC CDR3 of a VH having the amino acid sequence of SEQ ID NO: 34, and a LC CDR1, LC CDR2, and LC CDR3 of a VL having the amino acid sequence of SEQ ID NO: 80;#14704898vl(h) a HC CDR1, HC CDR2, and HC CDR3 of a VH having the amino acid sequence of SEQ ID NO: 36, and a LC CDR1, LC CDR2, and LC CDR3 of a VL having the amino acid sequence of SEQ ID NO: 71; or(i) a HC CDR1, HC CDR2, and HC CDR3 of a VH having the amino acid sequence of SEQ ID NO: 39, and a LC CDR1, LC CDR2, and LC CDR3 of a VL having the amino acid sequence of SEQ ID NO: 74;wherein the antibody is obtainable at high expression titer.

3. The anti-IL-13 antibody of claim 1 or 2, wherein antibody comprises:(a) an HC CDR1 having the amino acid sequence of SEQ ID NO: 2, a HC CDR2 having the amino acid sequence of SEQ ID NO: 20, a HC CDR3 having the amino acid sequence of SEQ ID NO: 4, a LC CDR1 having the amino acid sequence of SEQ ID NO: 44, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46;(b) an HC CDR1 having the amino acid sequence of SEQ ID NO: 2, a HC CDR2 having the amino acid sequence of SEQ ID NO: 3, a HC CDR3 having the amino acid sequence of SEQ ID NO: 4, a LC CDR1 having the amino acid sequence of SEQ ID NO: 69, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46;(c) an HC CDR1 having the amino acid sequence of SEQ ID NO: 2, a HC CDR2 having the amino acid sequence of SEQ ID NO: 28, a HC CDR3 having the amino acid sequence of SEQ ID NO: 4, a LC CDR1 having the amino acid sequence of SEQ ID NO: 33, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46;(d) an HC CDR1 having the amino acid sequence of SEQ ID NO: 2, a HC CDR2 having the amino acid sequence of SEQ ID NO: 28, a HC CDR3 having the amino acid sequence of SEQ ID NO: 4, a LC CDR1 having the amino acid sequence of SEQ ID NO: 69, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46;(e) an HC CDR1 having the amino acid sequence of SEQ ID NO: 2, a HC CDR2 having the amino acid sequence of SEQ ID NO: 20, a HC CDR3 having the amino acid sequence of SEQ ID NO: 4, a LC CDR1 having the amino acid sequence of SEQ ID NO: 69, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46; or#14704898vl(f) an HC CDR1 having the amino acid sequence of SEQ ID NO: 2, a HC CDR2 having the amino acid sequence of SEQ ID NO: 37, a HC CDR3 having the amino acid sequence of SEQ ID NO: 4, a LC CDR1 having the amino acid sequence of SEQ ID NO: 44, LC CDR2 having the amino acid sequence of SEQ ID NO: 45, and LC CDR3 having the amino acid sequence of SEQ ID NO: 46.

4. The anti-IL-13 antibody of any one of claims 1-3, comprising:(a) a VH having the amino acid sequence of SEQ ID NO: 19, and a VL having the amino acid sequence of SEQ ID NO: 63;(b) a VH having the amino acid sequence of SEQ ID NO: 24, and a VL having the amino acid sequence of SEQ ID NO: 66;(c) a VH having the amino acid sequence of SEQ ID NO: 24, and a VL having the amino acid sequence of SEQ ID NO: 80;(d) a VH having the amino acid sequence of SEQ ID NO: 27, and a VL having the amino acid sequence of SEQ ID NO: 71;(e) a VH having the amino acid sequence of SEQ ID NO: 32, and a VL having the amino acid sequence of SEQ ID NO: 68;(f) a VH having the amino acid sequence of SEQ ID NO: 34, and a VL having the amino acid sequence of SEQ ID NO: 76;(g) a VH having the amino acid sequence of SEQ ID NO: 34, and a VL having the amino acid sequence of SEQ ID NO: 80;(h) a VH having the amino acid sequence of SEQ ID NO: 36, and a VL having the amino acid sequence of SEQ ID NO: 71; or(i) a VH having the amino acid sequence of SEQ ID NO: 39, and a VL having the amino acid sequence of SEQ ID NO: 74.

5. The anti-IL-13 antibody of any one of claims 1-3, comprising:a VH domain encoded by a sequence selected from Table 4a; anda VL domain encoded by a sequence selected from Table 4b.

6. The anti-IL-13 antibody of any one of claims 1-5, further comprising a heavy chain constant domain.

7. The anti-IL-13 antibody of any one of claims 1-6, further comprising a light chain constant domain.#14704898vl8. An isolated nucleic acid encoding the VH and / or the VL of the anti-IL-13 antibody of any one of claims 1-7.

9. The isolated nucleic acid of claim 8, wherein the isolated nucleic acid comprises:(a) a nucleic acid sequence of SEQ ID NO: 182, and / or a nucleic acid sequence of SEQ ID NO: 225;(b) a nucleic acid sequence of SEQ ID NO: 183, and / or a nucleic acid sequence of SEQ ID NO: 226;(c) a nucleic acid sequence of SEQ ID NO: 183, and / or a nucleic acid sequence of SEQ ID NO: 231;(d) a nucleic acid sequence of SEQ ID NO: 184, and / or a nucleic acid sequence of SEQ ID NO: 228;(e) a nucleic acid sequence of SEQ ID NO: 185, and / or a nucleic acid sequence of SEQ ID NO: 227;(f) a nucleic acid sequence of SEQ ID NO: 186, and / or a nucleic acid sequence of SEQ ID NO: 230;(g) a nucleic acid sequence of SEQ ID NO: 186, and / or a nucleic acid sequence of SEQ ID NO: 231;(h) a nucleic acid sequence of SEQ ID NO: 187, and / or a nucleic acid sequence of SEQ ID NO: 228; or(i) a nucleic acid sequence of SEQ ID NO: 188, and / or a nucleic acid sequence of SEQ ID NO: 229.

10. An expression vector comprising the isolated nucleic acid of any one of claims 8 or 9.

11. A host cell comprising the anti-IL-13 antibody of any one of claims 1-7, the isolated nucleic acid of claims 8 or 9, or the expression vector of claim 10.

12. The host cell of claim 11, wherein the host cell is a Chinese hamster ovary (CHO) cell or a human embryonic kidney 293 (HEK293) cell.

13. A method for producing the anti-IL-13 antibody of any one of claims 1-7, the method comprising:#14704898vl(i) culturing the host cell of claim 11 or 12 under conditions for expressing the anti-IL-13 antibody; and(ii) harvesting the anti-IL-13 antibody from a host cell lysate or culture supernatant.

14. The method of claim 13, further comprising purifying the anti-IL-13 antibody.

15. A composition comprising the anti-IL-13 antibody of any one of claims 1-7, the isolated nucleic acid of claims 8 or 9, the expression vector of claim 10, or the host cell of claims 11 or 12.

16. The composition of claim 15, further comprising a pharmaceutically acceptable carrier.

17. A method comprising administering to a subject in need thereof an effective amount of the anti-IL-13 antibody of any one of claims 1-7, the isolated nucleic acid of claims 8 or 9, the expression vector of claim 10, the host cell of claims 11 or 12, or the composition of claims 15 or 16.

18. The method of claim 17, wherein the subject has a skin barrier defect.

19. A method of treating a skin barrier defect, the method comprising administering to a subject an effective amount of the anti-IL-13 antibody of any one of claims 1-7, the isolated nucleic acid of claims 8 or 9, the expression vector of claim 10, the host cell of claims 11 or 12, or the composition of claims 15 or 16.

20. The method of claim 18 or 19, wherein the skin barrier defect is associated with Netherton syndrome, atopic dermatitis, eosinophilic esophagitis, prurigo nodularis, chronic pruritus of unknown origin (CPUO), dry skin, asthma, ichthyosis vulgaris, or itch or chronic itch.

21. The method of any one of claims 17-20, wherein the subject has atopic dermatitis.

22. An antibody comprising a heavy chain variable region that comprises a heavy chain complementarity determining region 1 (HC CDR1), HC CDR2, and HC CDR3 and a HC FW1, a HC FW2, a HC FW3 and a HC FW4 comprising the amino acid sequence of the HC FW1, HC FW2, HC FW3, and HC FW4 in Table 2, and a light chain complementarity determining region 1 (LC CDR1), LC CDR2, and LC CDR3 and a LC FW1, a LC FW2, a LC FW3 and a LC FW4 #14704898vlcomprising the amino acid sequence of any one of the HC FW1, HC FW2, HC FW3, and HC FW4 set forth in Table 2.

23. An antibody comprising:(a) a variable heavy chain (VH) domain in format heavy chain (HC) framework 1 (HC FW1)-HC complementarity determining 1 (CDRl)-HC FW2-HC CDR2-HC FW3-HC CDR3-HC FW4, wherein the HC FW1, HC FW2, HC FW3, and HC FW4 comprise the amino acid sequence of any one of the HC FW1, HC FW2, HC FW3, and HC FW4 selected from Table 3a; and(b) a variable light chain domain (VL) in format light chain (LC) FW1-LC CDR1-LC FW2-LC CDR2-LC FW3-LC CDR3-LC FW4, wherein the LC FW1, LC FW2, LC FW3, and LC FW4 comprise the amino acid sequence of any one of the LC FW1, LC FW2, LC FW3, and LC FW4 selected from Table 3b.

24. The antibody of claim 23, wherein the antibody comprises:(a) an HC FW1, HC FW2, HC FW3, and HC FW4 of a VH having the amino acid sequence of SEQ ID NO: 19;(b) an HC FW1, HC FW2, HC FW3, and HC FW4 of a VH having the amino acid sequence of SEQ ID NO: 24;(c) an HC FW1, HC FW2, HC FW3, and HC FW4 of a VH having the amino acid sequence of SEQ ID NO: 27;(d) an HC FW1, HC FW2, HC FW3, and HC FW4 of a VH having the amino acid sequence of SEQ ID NO: 32;(e) an HC FW1, HC FW2, HC FW3, and HC FW4 of a VH having the amino acid sequence of SEQ ID NO: 34;(f) an HC FW1, HC FW2, HC FW3, and HC FW4 of a VH having the amino acid sequence of SEQ ID NO: 36; or(g) an HC FW1, HC FW2, HC FW3, and HC FW4 of a VH having the amino acid sequence of SEQ ID NO: 39.

25. The antibody of claim 23 or 24, wherein the antibody comprises:(a) a HC FW1 having the amino acid sequence of SEQ ID NO: 21, a HC FW2 having the amino acid sequence of SEQ ID NO: 22, a HC FW3 having the amino acid sequence of SEQ ID NO: 23, and a HC FW4 having the amino acid sequence of SEQ ID NO: 8;#14704898vl(b) a HC FW1 having the amino acid sequence of SEQ ID NO: 25, a HC FW2 having the amino acid sequence of SEQ ID NO: 6, a HC FW3 having the amino acid sequence of SEQ ID NO: 26, and a HC FW4 having the amino acid sequence of SEQ ID NO: 8;(c) a HC FW1 having the amino acid sequence of SEQ ID NO: 29, a HC FW2 having the amino acid sequence of SEQ ID NO: 30, a HC FW3 having the amino acid sequence of SEQ ID NO: 31, and a HC FW4 having the amino acid sequence of SEQ ID NO: 8;(d) a HC FW1 having the amino acid sequence of SEQ ID NO: 29, a HC FW2 having the amino acid sequence of SEQ ID NO: 30, a HC FW3 having the amino acid sequence of SEQ ID NO: 33, and a HC FW4 having the amino acid sequence of SEQ ID NO: 8;(e) a HC FW1 having the amino acid sequence of SEQ ID NO: 35, a HC FW2 having the amino acid sequence of SEQ ID NO: 22, a HC FW3 having the amino acid sequence of SEQ ID NO: 23, and a HC FW4 having the amino acid sequence of SEQ ID NO: 8;(f) a HC FW1 having the amino acid sequence of SEQ ID NO: 21, a HC FW2 having the amino acid sequence of SEQ ID NO: 22, a HC FW3 having the amino acid sequence of SEQ ID NO: 38, and a HC FW4 having the amino acid sequence of SEQ ID NO: 8; or(g) a HC FW1 having the amino acid sequence of SEQ ID NO: 40, a HC FW2 having the amino acid sequence of SEQ ID NO: 41, a HC FW3 having the amino acid sequence of SEQ ID NO: 42, and a HC FW4 having the amino acid sequence of SEQ ID NO: 8.

26. The antibody of any one of claims 23-25, wherein the antibody comprises:(a) a LC FW1, LC FW2, LC FW3, and LC FW4 of a VL having the amino acid sequence of SEQ ID NO: 63;(b) a LC FW1, LC FW2, LC FW3, and LC FW4 of a VL having the amino acid sequence of SEQ ID NO: 66;(c) a LC FW1, LC FW2, LC FW3, and LC FW4 of a VL having the amino acid sequence of SEQ ID NO: 80;(d) a LC FW1, LC FW2, LC FW3, and LC FW4 of a VL having the amino acid sequence of SEQ ID NO: 71;(e) a LC FW1, LC FW2, LC FW3, and LC FW4 of a VL having the amino acid sequence of SEQ ID NO: 68;(f) a LC FW1, LC FW2, LC FW3, and LC FW4 of a VL having the amino acid sequence of SEQ ID NO: 76; or(g) a LC FW1, LC FW2, LC FW3, and LC FW4 of a VL having the amino acid sequence of SEQ ID NO: 74..#14704898vl27. The antibody of any one of claims 23-26, wherein the antibody comprises:(a) a LC FW1 having the amino acid sequence of SEQ ID NO: 47, a LC FW2 having the amino acid sequence of SEQ ID NO: 48, a LC FW3 having the amino acid sequence of SEQ ID NO: 64, a LC FW4 having the amino acid sequence of SEQ ID NO: 65;(b) a LC FW1 having the amino acid sequence of SEQ ID NO: 67, a LC FW2 having the amino acid sequence of SEQ ID NO: 48, a LC FW3 having the amino acid sequence of SEQ ID NO: 64, a LC FW4 having the amino acid sequence of SEQ ID NO: 65;(c) a LC FW1 having the amino acid sequence of SEQ ID NO: 77, a LC FW2 having the amino acid sequence of SEQ ID NO: 78, a LC FW3 having the amino acid sequence of SEQ ID NO: 81, a LC FW4 having the amino acid sequence of SEQ ID NO: 65;(d) a LC FW1 having the amino acid sequence of SEQ ID NO: 72, a LC FW2 having the amino acid sequence of SEQ ID NO: 48, a LC FW3 having the amino acid sequence of SEQ ID NO: 73, a LC FW4 having the amino acid sequence of SEQ ID NO: 65;(e) a LC FW1 having the amino acid sequence of SEQ ID NO: 70, a LC FW2 having the amino acid sequence of SEQ ID NO: 57, a LC FW3 having the amino acid sequence of SEQ ID NO: 58, a LC FW4 having the amino acid sequence of SEQ ID NO: 65;(f) a LC FW1 having the amino acid sequence of SEQ ID NO: 77, a LC FW2 having the amino acid sequence of SEQ ID NO: 78, a LC FW3 having the amino acid sequence of SEQ ID NO: 79, a LC FW4 having the amino acid sequence of SEQ ID NO: 65; or(g) a LC FW1 having the amino acid sequence of SEQ ID NO: 72, a LC FW2 having the amino acid sequence of SEQ ID NO: 48, a LC FW3 having the amino acid sequence of SEQ ID NO: 75, a LC FW4 having the amino acid sequence of SEQ ID NO: 65.

28. An antibody comprising an antigen-specific binding site and a framework,wherein the antigen-specific binding site comprises a heavy chain complementarity determining region 1 (HC CDR1), HC CDR2, and HC CDR3; andwherein the HC CDR1, HC CDR2, and HC CDR3 are grafted into a heavy chain framework (HC FW) of any one of the HC variable domains (VL) in Table 2.

29. An antibody comprising an antigen-specific binding site and a framework,wherein the antigen-specific binding site comprises a light chain complementarity determining region 1 (LC CDR1), LC CDR2, and LC CDR3; andwherein the LC CDR1, LC CDR2, and LC CDR3 are grafted into a light chain framework (LC FW) of any one of the LC variable domains (VL) in Table 2.#14704898vl30. A method of producing a humanized antibody, the method comprising engineering a recombinant nucleic acid to express an antibody having a selected set of complementarity determining regions (CDRs) engrafted in any one of the framework (FW) sets selected from Table 3a and / or Table 3b.#14704898vl

Images